

VENMAX DRUGS AND PHARMACEUTICALS LIMITED

37th ANNUAL REPORT 2025-2026

CONTENTS

Corporate Information	04
Notice of the 37 th Annual General Meeting.....	05-15
Board’s Report	16-22
Annexures	23-42
Independent Auditor’s Report	43-51
Standalone Financial Statement	52-68

CORPORATE INFORMATION

BOARD OF DIRECTORS:

- | | | |
|----|--------------------------------|--|
| 1) | Mr. Venkata Rao Sadhanala | Managing Director |
| 2) | Mr. Gundluru Reddeppa | Non-Executive, Independent Director |
| 3) | Mr. Swapneswar Mishra | Non-Executive, Non- Independent Director |
| 4) | Mr. Dasi Reddy Rakesh | Non-Executive, Non-Independent Director |
| 5) | Mrs. Padmaja Kalyani Sadhanala | Additional Director (Non-Executive, Non-Independent) |
| 6) | Mr. Revoor Ramachandra | Additional Director (Non-Executive, Independent) |

REGISTERED OFFICE/CORPORATE OFFICE:

Sy.No.115, Brig Sayeed Road
Hanumanji Colony, Bowenpally
Picket, Hyderabad, Secunderabad
Telangana, 500009
Email: venmaxdrugs@gmail.com
Website: www.venmaxdrugs.com

STATUTORY AUDITORS:

M/S PPKG & CO
Chartered Accountants
Hyderabad

REGISTRAR & SHARE TRANSFER

AGENTS (RTA):

M/s. CIL Securities Limited
214, Raghavaratna Towers, Chirag Ali Lane
Hyderabad-500001, Telangana
Email: rta@cilsecurities.com

LISTING:

BSE Limited

BANKERS:

ICICI Bank Limited
Kharkhana Branch

NOTICE

NOTICE IS HEREBY GIVEN THAT THE 37th ANNUAL GENERAL MEETING OF THE MEMBERS OF VENMAX DRUGS AND PHARMACEUTICALS LIMITED ("THE COMPANY") WILL BE HELD ON SATURDAY, 26th DAY OF SEPTEMBER 2026 AT 12.30 P.M. IST THROUGH VIDEO CONFERENCING/ OTHER AUDIO-VISUAL MEANS ("VC/OAVM") TO TRANSACT THE FOLLOWING BUSINESS:

Ordinary Business:

1. To receive, consider and adopt the Standalone Audited Financial Statements of the Company for the Financial Year ended March 31, 2026, together with the Report of the Directors and Auditors thereon and in this regard, to give assent or dissent to the following resolution as an Ordinary Resolution:

"RESOLVED THAT the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2026 including the Audited Balance Sheet as at March 31, 2026, the Statement of Profit and Loss for the year ended on that date and the Reports of the Board of Directors and Auditors thereon, be and are hereby received, considered and adopted."

2. To appoint a director in place of Mr. Swapneswar Mishra (DIN: 09594775), who retires by rotation at this Meeting as a Director and being eligible, offers himself for re-appointment and in this regard, to give assent or dissent to the following Resolution as an Ordinary Resolution.

"RESOLVED THAT Mr. Swapneswar Mishra (DIN: 09594775), who retires by rotation at this Meeting and being eligible has offered himself for re-appointment, be and is hereby re-appointed as a Director of the Company, liable to retire by rotation."

Special Business:

3. To approve Change in designation of Mr. Venkata Rao Sadhanala, (DIN: 02906370) from Whole Time Director to Managing Director of the Company

To Consider and if thought fit, to pass the following with or without modification(s) as an Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, and 203 read with Schedule V and all other applicable provisions, if any, of the Companies Act, 2013, and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), and subject to the provisions of the Articles of Association of the Company, and on recommendation of Nomination & Remuneration Committee, the approval of the members of the Company be and is hereby accorded to change the designation of Mr. Venkat Rao Sadhanala, (DIN:02906370) from Whole-time Director to Managing Director of the Company, for a period of 5 years with effect from March 11, 2026 to 10th March 2031, with a remuneration of ₹30,00,000/- (Rupees Thirty Lakhs only) p.a. on such other terms and conditions, as set out in the Explanatory Statement annexed hereto.

"RESOLVED FURTHER THAT the Board of Directors of the Company (hereinafter referred to as "the Board", which term shall include any Committee constituted/to be constituted by the Board) be and is hereby authorized to alter, vary, or modify the terms and conditions of the said appointment and/or remuneration from time to time, in such manner as may be agreed between the Board and Mr. Venkata Rao Sadhanala, subject to the limits prescribed under Section 197 and Schedule V of the Companies Act, 2013."

"RESOLVED FURTHER THAT any Director of the Company or the Company Secretary be and is hereby authorized to sign and file the necessary forms with the Registrar of Companies (ROC), and to do all such acts, deeds, matters, and things as may be necessary, expedient, or desirable to give effect to this resolution."

4. To Regularize the Appointment of Mrs. Padmaja kalyani Sadhanala (DIN:03096445), Additional Director as Non-Executive Non-Independent Director of the Company.

To consider and, if thought fit, to pass with or without modifications, the following resolution as Ordinary Resolution:

“RESOLVED THAT Mrs. Padmaja Kalyani Sadhanala (DIN: 03096445), who was appointed as an Additional Director w.e.f. March 30, 2026 by the Board of Directors on the recommendation of Nomination and Remuneration Committee and who holds office up to the conclusion of this Annual General Meeting in terms of Section 161(1) of the Companies Act, 2013 (the “Act”) and who is eligible for appointment and has consented to act as Director of the Company and in respect of whom the Company has received a notice in writing from a Member under Section 160 of the Act proposing her candidature for the office of Director, be and is hereby appointed as a Non-Executive Non-Independent Director of the Company and whose office is liable to retire by rotation.”

RESOLVED FURTHER THAT the Directors of the Company be and are hereby severally authorized to do all such acts, deeds and things as may be required to give effect to the above resolution.”

5. **To Regularize the appointment of Mr. Revoor Ramachandra (DIN: 00490051), Additional Director as Non-Executive Independent Director of the Company.**

To consider and, if thought fit, to pass with or without modification, the following resolution as **Special Resolution**:

“RESOLVED THAT pursuant to the provisions of Sections 149, 152 and other applicable provisions, if any, of the Companies Act, 2013 (the “Act”) , the Companies (Appointment and Qualifications of Directors) Rules, 2014, read with Schedule IV of the Act and pursuant to applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”), as amended from time to time, of Mr. Revoor Ramachandra (DIN:00490051), who was appointed as an Additional Director- Independent of the Company with effect from March 30, 2026 by the board of directors on the recommendation of the Nomination and Remuneration Committee and who holds office up to the date of this Annual General Meeting of the Company in terms of Section 161(1) of the Act and in respect of whom the Company has received a notice in writing from a member under Section 160(1) of the Act proposing his candidature for the office of Director of the Company and also a written declaration in conformity with SEBI (LODR) Regulations, 2015, be and is hereby appointed as Director of the Company under Independent Category of the company, not liable to retire by rotation, for a First Term of five (5) consecutive years commencing from March 30, 2026 up to March 29, 2031.

RESOLVED FURTHER THAT the Directors of the Company be and are hereby severally authorized to do all such acts, deeds and things as may be required to give effect to the above resolution.”

Date: August 31, 2026
Place: Hyderabad

By Order of the Board
for Venmax Drugs and Pharmaceuticals Limited

Sd/-
Venkata Rao Sadhanala
Managing Director
(DIN: 02906370)

NOTES:

1. The Explanatory Statement setting out the material facts pursuant to Section 102 of the Companies Act, 2013 ("the Act"), in respect of the Special Business and the details as required under Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') entered with the Stock Exchanges and Secretarial Standard on General Meeting (SS-2) in respect of the Directors seeking appointment / re-appointment at this Annual General Meeting is annexed hereto.
2. The Ministry of Corporate Affairs (MCA) vide General Circular No. 14/2020 dated 08.04.2020, General Circular No. 17/2020 dated 13.04.2020, General Circular No. 22/2020 dated 15.06.2020, General Circular No. 33/2020 dated 28.09.2020, General Circular No. 39/2020 dated 31.12.2020, General Circular No. 10/2021 dated 23.06.2021, General Circular No. 20/2021 dated 08.12.2021, General Circular No. 3/2022 dated 05.05.2022, and General Circular No. 10/2022 dated 28.12.2022, General Circular No. 09/2023 dated 25.09.2023 and 09/2024 dated September 19, 2024, and 03/2025 dated September 22, 2025 (collectively referred to as "MCA Circulars") has permitted holding of AGM through Video Conferencing (VC) or Other Audio Visual Means (OAVM) on or before 30.09.2026. Hence, in compliance with the provisions of the Companies Act, 2013 ("Act"), SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and MCA Circulars and SEBI Circulars, the 37th AGM of the Company is being held through VC / OAVM on Saturday, September 26, 2026 at 12:30 P.M. (IST).

In compliance of Section 20 of the Companies Act, 2013 and further to the aforesaid MCA Circulars and SEBI Circulars, notice of the 37th AGM along with the Annual Report 2025-26 is being sent only through electronic mode to the Members whose e-mail addresses are registered with the Company/ Depositories. Members may note that the Notice and the Annual Report 2025-26 will also be available on the Company's Website: www.venmaxdrugs.com and Website of the Stock Exchange i.e., BSE Limited: <https://www.bseindia.com>, and on the Website of CDSL: <https://www.evotingindia.com>.

3. Green Initiative: To support the Green Initiative, Members who have not registered their e-mail address are requested to register their e-mail address for receiving all the communications through Annual Report from the Company electronically.
4. A Member entitled to attend and vote at the AGM is entitled to appoint a Proxy to attend and vote on his / her behalf and the Proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars and SEBI Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of Proxies by the Members will not be available for the AGM and hence the Proxy Form, Attendance Slip and Route Map are not annexed to this Notice.
5. Members of the Company under the category of Institutional Investors are encouraged to attend and vote at the AGM through VC/OAVM. Corporate Members intending to authorize their Representatives to participate and vote at the AGM are requested to upload a copy of the Board Resolution/Authorization Letter on the E-Voting Portal or send to the Company at Venmaxdrugs@gmail.com.
6. Members attending the AGM through VC / OAVM shall be counted for the purpose of reckoning the Quorum under Section 103 of the Act. As per Regulation 40 of the SEBI Listing Regulations, as amended, Securities of Listed Entities can be transferred only in Dematerialized form with effect from April 1 2019, except in case of transmission or transposition of Securities. In view of this, Members holding Shares in Physical Form are requested to consider converting their holdings to Dematerialized form. Members can contact M/s. CIL securities Limited, 214, Raghavaratna Towers, Chirag Ali Lane, Hyderabad, 500001, Telangana, Email: rta@cilsecurities.com for assistance in this regard.
7. Members are requested to intimate changes, if any, pertaining to their Name, Postal Address, E-mail Address, Telephone/Mobile Numbers, Permanent Account Number, Mandates, Nominations, Power of Attorney, Bank Details viz., Name of the Bank, Branch Details, Bank Account Number, MICR Code, IFSC Code etc., to their Depository Participants ("DPs") in case the Shares are held in Electronic Form and
 - a. Registrar/RTA in case the Shares are held in Physical Form. Registration of E-mail for Shareholders holding Physical Shares: Members holding Shares in Physical Form and who have not registered their E-mail addresses may get their E-mail addresses registered with the Registrar, by referring to their website: Email: rta@cilsecurities.com and follow the Registration Process as guided therein. Members are requested to provide details such as Name, Folio Number, Certificate Number, PAN, Mobile Number and E-mail and also upload the image

of Share Certificate in PDF or JPEG format. On submission of the details, an OTP will be received by the Member which needs to be entered in the link for verification. For Permanent Registration for Demat Shareholders: It is clarified that for permanent registration of E-mail address, Members are requested to register their E-mail address, in respect of Demat holdings with the respective Depository Participant (DP) by follow the procedure as prescribed by the Depository Participant.

- b. For Temporary Registration for Demat Shareholders: Members holding Shares in Physical Form and who have not registered their E-mail addresses may get their E-mail addresses registered with the Registrar, by referring to their website: Email: rta@cilsecurities.com and follow the Registration Process as guided therein. Members are requested to provide details such as Name, Folio Number, Certificate Number, PAN, Mobile Number and E-mail.
 - c. Registration of Bank Details for Physical Shareholders: Members holding Shares in Physical Form and who have not registered their Bank details can get the same registered with the Registrar, by clicking the rta@cilsecurities.com and follow the registration process as guided therein. Members are requested to provide details such as Name, Folio Number, Share Certificate Number, PAN, E-mail, along with the copy of the Cheque Leaf with the First named Member as mentioned on the Cheque Leaf containing Bank Name and Branch, Type of Account, Bank Account Number, MICR Details and IFSC code in PDF or JPEG format. It is very important that the Member should submit the request letter duly signed. The Registrar will verify the documents upload and will only take on records for all valid cases. On submission of the details, an OTP will be received by the Member which needs to be entered in the link for verification.
8. The Meeting shall be deemed to be held at the registered office of the Company at Sy.No.115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Secunderabad, 500009, Telangana, India.
 9. Nomination: Pursuant to Section 72 of the Companies Act, 2013, Members holding Shares in Physical Form are advised to file Nomination in the prescribed Form SH-13 with the Company's Share Transfer Agent. In respect of the Shares held in dematerialized form, Members may please contact their respective Depository Participant.
 10. Consolidation of Physical Share Certificates: Members holding Shares in Physical Form, in identical order of Names, in more than One Folio are requested to send to the Company or Registrar, the details of such Foliros together with the Share Certificates for consolidating their holdings in One Folio. A Consolidated Share Certificate will be issued to such Members after making requisite changes.
 11. In compliance with the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI Listing Regulations, the Company has provided a facility to its Members to cast their vote electronically, through the E-Voting services provided by Central Depository Services (India) Limited ("CDSL") on all the Resolutions set forth in this Notice. Members who have cast their Votes by remote E-Voting prior to the AGM may also participate in the AGM through VC but shall not be entitled to cast their Vote on such Resolutions again. The manner and process of E-Voting remotely by Members is provided in the instructions for E-Voting which forms part of this Notice.
 12. A Person, whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off Date for dispatch of Notice and Annual Report i.e., **August 28, 2026** will only be entitled for receipt of Annual Report.
 13. The Voting Rights of the Shareholders for voting through remote E-Voting at the AGM shall be in proportion to their share of the Paid-up Equity Share Capital of the Company as on **Friday 18th September, 2026 ('Cut-Off Date')**. A Person whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off Date, only shall be entitled to avail the facility of remote E-Voting or of voting at the AGM and who is not a Member as on the Cut-off Date shall treat this Notice for information purposes only.
 14. The Remote E-Voting Period will commence on **Wednesday, 23rd September, 2026 (IST 09:00 A.M.) and will end on Friday, 25th September, 2026 (IST 05:00 P.M.)**. During this period, Members of the Company, holding Shares in dematerialized form, as on the Cut-off Date i.e., on **Friday, 18th September, 2026 ('Cut-Off Date')** shall be entitled to cast their vote by remote E-Voting. Once the Vote on a Resolution is cast by the Member, the Member shall not be allowed to change it subsequently.
 15. The facility for Voting during the AGM will also be made available. Members present in the AGM through VC and who have not casted their Vote on the Resolutions through remote E-Voting and are

otherwise not barred from doing so, shall be eligible to Vote through E-Voting system during the AGM. Any person who becomes a Member of the Company after sending the Notice and holding Shares as on the **Cut-off date (Friday, 18th September, 2026)** may obtain the Login-id and Password by sending a request at helpdesk.evoting@cdslindia.com. However, if a member is already registered with CDSL for remote E-Voting then he/she can use his/her existing User-id and Password for casting the Vote.

16. In case of Joint holders, the Joint holder who is higher in the order of Names, will be entitled to vote at the Meeting, if not already voted through remote E-Voting.

Members seeking any information with regard to the accounts or any matter to be placed at the AGM, are requested to write to the Company mentioning their Name, Demat Account Number/Folio Number, E-mail, Mobile Number at venmaxdrugs@gmail.com on or before **Friday, 18th September, 2026**. The same will be replied by the Company suitably.

17. In case of Joint holders, the Joint holder who is higher in the order of Names, will be entitled to vote at the Meeting, if not already voted through remote E-Voting.
18. The Board of Directors has appointed PCS Kashinath Sahu, Proprietor of Kashinath Sahu & Co., Practicing Company Secretaries (Firm No: No. 4807), Hyderabad as the Scrutinizer to scrutinize the remote E-Voting Process and voting during the AGM, in a fair and transparent manner.
19. The Scrutinizer shall immediately, after the conclusion of E-Voting at the AGM, first count the Votes Cast during the AGM, thereafter, unblock the Votes Cast through remote E-Voting and make, not later than 2 working dates of conclusion of the AGM, a consolidated Scrutinizer's Report of the Total Votes Cast in favor or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same. The Results declared along with the Scrutinizer's Report shall be placed on the Website of the Company and on the Website of CDSL immediately. The results will also be communicated to BSE Limited, where the Shares of the Company are listed.
20. To prevent fraudulent transactions, Members are advised to exercise Due Diligence and notify the Company of any change in address or Demise of any Member as soon as possible. Members are also advised not to leave their Demat account(s) dormant for long. Periodic Statement of Holdings should be obtained from the concerned DPs and Holdings should be verified from time to time.
21. **Instructions for attending the AGM through VC / OAVM:**

Shareholder will be provided with a facility to attend the AGM through VC/OAVM through the CDSL E-Voting system. Shareholders may access the same at <https://www.evotingindia.com> under Shareholders / Members login by using the remote E-Voting credentials. The link for VC/OAVM will be available in Shareholder / Members login where the EVSN of the Company is displayed.

Members may join the Meeting through Laptops, Smartphones, Tablets and I-Pads for better experience. Further, Members will be required to use the Internet with a good speed to avoid any disturbance during the Meeting. Please note that participants connecting from Mobile Devices or Tablets or through Laptops connecting via mobile hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use stable Wi-Fi or LAN connection to mitigate any glitches.

Shareholders who would like to express their views / ask questions during the Meeting may register themselves as a speaker by sending their request in advance **to reach on or before 23rd September, 2026** from their registered E-mail address mentioning their names, DP-ID and ClientID / Folio Number, PAN and Mobile Number at venmaxdrugs@gmail.com. Only those Members who have pre-registered themselves as a speaker will be allowed to express their views / ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.

Members are encouraged to submit their questions in advance with regard to the Financial Statements or any other matter to be placed at the 37th AGM, from their registered E-mail address, mentioning their Name, DP-ID and Client-ID Number / Folio Number and Mobile Number, to reach the Company's E-mail address at venmaxdrugs@gmail.com before **5:00 P.M. (IST) on Wednesday, 23rd September, 2026**. Such questions by the Members shall be suitably replied by the Company.

Those Shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the Meeting. If any votes are cast by the Shareholders through the E-Voting available during the AGM and if the same Shareholders have not participated in the Meeting through VC / OAVM facility, then the votes cast by such Shareholders shall be considered as invalid, as the facility of E-Voting during the Meeting is available only to the Shareholders attending the Meeting.

22. Subject to the receipt of Requisite number of Votes, the Resolutions forming part of the AGM Notice shall be deemed to be passed on the date of the AGM. Voting through Electronic Means: Pursuant to Section 108 of the Companies Act, 2013 and Rule 20 read with the Companies (Management and Administration) Rules, 2014 read with amendments or re-enactments made thereunder and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Company is pleased to provide the facility to exercise Members' Right to Vote at the 37th Annual General Meeting (AGM) by electronic means and the business may be transacted through E-Voting Services provided by Central Depository Services (India) Limited (CDSL). The Members attending the Meeting, who have not already cast their vote through Remote E-Voting shall be able to exercise their Voting Rights at the Meeting. The Members who have already cast their vote through Remote E-Voting may attend the Meeting but shall not be entitled to cast their vote again at the AGM.
23. The instructions for Shareholders for Voting Electronically are as under:
- The Voting Period commences on Wednesday, 23rd September, 2026 (09:00 A.M.) and closes on Friday, 25th September, 2026 (05:00 P.M.)** During this period, the Shareholders of the Company, holding Shares in Dematerialized Form, as on the Cut-off Date (Record Date), **Friday, 18th September, 2026** may cast their vote electronically. The E-Voting Module shall be disabled by CDSL for Voting thereafter.
 - Shareholders who have already voted prior to the Meeting Date would not be entitled to vote at the Meeting.

Login method for E-Voting and Joining Virtual Meetings for Individual Shareholders holding Securities in Demat Mode:

Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/ CIR/P/2020/242 dated 9th December 2020 on "E-Voting Facility provided by Listed Companies", Individual Shareholders holding Securities in Demat mode are allowed to cast their vote through their Demat Account maintained with the Depositories and Depository Participants. Shareholders are advised to update their Mobile Number and E-mail in their Demat Accounts in order to access the E-Voting Facility. Pursuant to the above said SEBI Circular, Login method for E-Voting and joining Virtual Meetings for Individual Shareholders holding Securities in Demat mode CDSL/NSDL is given below:

Type of Shareholders	Login Method
Individual Shareholders Holding Securities in Demat Mode with CDSL Depository	- Users who have opted for CDSL EASI/EASIEST facility, can login through their existing User-id and Password. Option will be made available to reach E-Voting page without any further authentication. The URL for Users to login to EASI/ EASIEST are https://web.cdslindia.com/myeasi/home/ login or visit www.cdslindia.com and click on Login icon and select New System MYEASI. - After successful login to the EASI/EASIEST User will be able to see the E-Voting option for eligible Companies where the E-Voting is in progress as per the information provided by Company. On clicking the E-Voting option, the User will be able to see E-Voting page of the E-Voting Service Provider for casting your Vote during the remote E-Voting period or joining Virtual Meeting and Voting during the Meeting. Additionally, there are also links provided to access the system of all E-Voting Service Providers i.e. CDSL/NSDL/ KARVY/LINKINTIME so that the User can visit the E-Voting Service Providers website directly. - If the user is not registered for EASI/ EASIEST, option to register is available at CDSL website www.cdslindia.com. To login click on login & New System MYEASI Tab and then click on registration option. - Alternatively, the User can directly access E-Voting Page by providing Demat Account Number and PAN on E-Voting link available on www.cdslindia.com homepage. The system will authenticate the User by sending OTP on the Registered Mobile and E-mail as recorded in the Demat Account. After successful authentication, the User will be able to see the E-Voting option where the E-Voting is in progress and also able to directly access the system of all the E-Voting Service Providers.

Individual Shareholders Holding Securities in Demat Mode with NSDL Depository	1. If you are already registered for NSDL 'IDeAS' facility, please visit the E-services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a Mobile. Once the Homepage of E-services is launched Click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' Section. A new screen will open. You will have to enter your User-id and Password. After successful authentication, you will be able to see E-Voting Services. Click on "Access to E-Voting" under E-Voting Services and you will be able to see E-Voting page. Click on Company name or E-Voting Service Provider name and you will be re-directed to E-Voting Service Provider website for casting your vote during the remote E-Voting period or joining Virtual Meeting and Voting during the Meeting. 2. If the User is not registered for IDeAS E-services, option to register is available at https://eservices.nsdl.com/ Select "Register Online for IDeAS" Portal or Click at https:// eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3. Visit the E-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the homepage of E-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User- id (i.e. your sixteen-digit Demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository Site wherein you can see E-Voting page. Click on Company name or E-Voting Service Provider name and you will be redirected to E-Voting Service Provider Website for casting your Vote during the remote E-Voting period or joining Virtual Meeting and Voting during the Meeting.
Individual Shareholders Holding Securities in Demat Mode Login through their Depository Participants (DP)	You can also login using the login credentials of your Demat account through your Depository Participant registered with NSDL/CDSL for E-Voting facility. After Successful login, you will be able to see E-Voting option. Once you click on E-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see E-Voting feature. Click on Company Name or E-Voting Service Provider name and you will be redirected to E-Voting Service Provider Website for casting your vote during the remote E- Voting period or joining Virtual Meeting and voting during the Meeting

Important note: Members who are unable to retrieve User-id / Password are advised to use Forgot User-id and Forgot Password option available at above mentioned website.

Helpdesk for Individual Shareholders holding Securities in Demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders Holding Securities in Demat Mode with CDSL	Members facing any technical issue in login can contact CDSL Helpdesk by sending a request at the following e-mail: helpdesk.evoting@cdslindia.com or Contact at a Toll-Free no. 1800 22 5533.
Individual Shareholders Holding Securities in Demat Mode with NSDL	Members facing any technical issue in login can contact NSDL Helpdesk by sending a request at evoting@nsdl.co.in or Call at Toll Free No. 1800 10 20990 and 1800 22 4430.

Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode

- i. The Shareholders should log on to the E-Voting Website: www.evotingindia.com
- ii. Click on “SHAREHOLDERS” Module.
- iii. Now enter your User-id.
 - i. For CDSL: 16 Digits Beneficiary ID.
 - ii. For NSDL: 8 Character DP-ID followed by 8 Digits Client-ID.
 - iii. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- iv. Next enter the ‘Image Verification’ as displayed and Click on Login.
- v. If you are holding Shares in Demat form and had logged on to www.evotingindia.com and had voted on an earlier E-Voting of any Company, then your existing password is to be used.
- vi. If you are a first-time user follow the steps given below:

For Physical Shareholders and other than Individual Shareholders holding Shares in Demat Form

PAN	Enter your 10-digit alpha-numeric PAN issued by Income Tax Department (Applicable for both Demat Shareholders as well as Physical Shareholders). Shareholders who have not updated their PAN with the Company / Depository Participant are requested to use the sequence number sent by Company / RTA or contact Company / RTA.
Dividend Bank Details or Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your Demat Account or in the Company Records in order to login. If both the details are not recorded with the Depository or Company, please enter the Member-id / Folio Number in the ‘Dividend Bank Details’ field.

- vii. After entering these details appropriately, click on ‘SUBMIT’ tab.
- viii. Shareholders holding Shares in Physical Form will then directly reach the Company selection screen. However, Shareholders holding Shares in Demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the ‘New Password’ field. Kindly note that this password is to be also used by the Demat Holders for Voting for Resolutions of any other Company on which they are eligible to vote, provided that the Company opts for E-Voting through CDSL Platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- ix. For Shareholders holding shares in Physical Form, the details can be used only for E-Voting on the Resolutions contained in this Notice.

Click on the EVSN of the relevant Company (‘VENMAX DRUGS AND PHARMACEUTICALS LIMITED’) on which you choose to vote.

- x. On the Voting Page, you will see ‘RESOLUTION DESCRIPTION’ and against the same the option ‘YES/ NO’ for Voting. Select the option ‘YES’ or ‘NO’ as desired. The option ‘YES’ implies that you assent to the Resolution and option ‘NO’ implies that you dissent to the Resolution.
- xi. Click on the ‘RESOLUTIONS FILE LINK’ if you wish to view the entire Resolution details.
- xii. After selecting the Resolution, you have decided to vote on, click on ‘SUBMIT’. A Confirmation Box will be displayed. If you wish to confirm your vote, click on ‘OK’, else to change your vote, click on ‘CANCEL’ and accordingly modify your vote.
- xiii. Once you ‘CONFIRM’ your vote on the resolution, you will not be allowed to modify your Vote.
- xiv. You can also take a print of the votes cast by clicking on ‘Click here to Print’ option on the Voting Page.

xv. If a Demat Account Holder has forgotten the login password, then enter the User-id and the 'Image Verification Code' and click on Forgot Password and enter the details as prompted by the system.

xvi. Additional Facility for Non - Individual Shareholders and Custodians - For Remote Voting:

- Non-Individual Shareholders (i.e. Other than Individuals, HUF, NRI etc.) and Custodians are required to log on to the website: www.evotingindia.com and register themselves in the 'CORPORATES' Module.
- A Scanned copy of the Registration Form bearing the Stamp and Sign of the Entity should be mailed to helpdesk.evoting@cdslindia.com.
- After receiving the login details, a Compliance User should be created using the admin login and Password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The List of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- It is Mandatory that a Scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favor of the Custodian, if any, should be uploaded in PDF format in the system for the Scrutinizer to verify the same.
- Alternatively, Non-Individual Shareholders are required to send the relevant Board Resolution/Authority Letter etc. together with the Attested Specimen Signature of the Duly Authorized Signatory who are authorized to vote, to the Scrutinizer and to the Company at the E-mail address: venmaxdrugs@gmail.com if they have voted from individual tab and not uploaded same in the CDSL E-Voting System for the Scrutinizer to verify the same.

If you have any queries or issues regarding E-Voting from the CDSL E-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at 022-23058738 and 022-23058542/43.

All grievances connected with the facility for Voting by electronic means may be addressed to Shri Rakesh Dalvi, Sr Manager, Central Depository Services (India) Limited (CDSL), Wing-A, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai-400013 or send an E-mail to helpdesk.evoting@cdslindia.com or call on 022-23058542/43.

Date: August 31, 2026
Place: Hyderabad

By Order of the Board of Directors

Sd/-

Venkata Rao Sadhanala
Managing Director
(DIN: 02906370)

“ANNEXURE - A”

TO THE NOTICE OF THE AGM

Details of Directors seeking appointment/re-appointment at the ensuing Annual General Meeting

[Pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard 2 on General Meetings issued by the Institute of Company Secretaries of India]

Name of the Director	Swapneswar Mishra	Venkata Rao Sadhanala	Padmaja Kalyani Sadhanala	Revoor Ramachandra
DIN	09594775	02906370	03096445	00490051
Date of Birth	12.07.1980	25.12.1963	27.12.1971	27.12.1959
Age	46	63	55	67
Date of first appointment on the Board	16.01.2024	01.10.2024	30.03.2026	30.03.2026
Qualification	Commerce Graduate	CA & CS	Post Graduation	Post Graduation
Experience	20 Years	32 Years	20 Years	42 Years
Terms and conditions of appointment	Liable to retire by Rotation	Change in Designation from Whole Time Director to Managing Director For a period of 5 Years w.e.f. March 11,2026 with a remuneration of Rs. 30 Lakhs p.a.	Liable to retire by Rotation	First Term of 5 Years
Nature of expertise in specific functional area	Finance & Accounts	Mergers, Acquisitions, Corporates, Strategies	Pharmaceutical Industry	Defence, Aero space, Auto motive components
Remuneration last drawn	Nil	Nil	Nil	Nil
Inter-se relationship with other directors and key managerial personnel	NA	He is spouse of the of the director of the Company	She is the spouse of the Managing Director of the Company	NA
List of Directorship	- Somani Herbs and Agro products (India) Pvt Ltd - Citrus Capital Services Pvt Ltd	- Omega Ag Seeds Punjab Limited - Mipco Seamless Rings Gujarat Limited	Blue Nile Capital Advisory Limited	Precosion Metaliks Limited
Membership/ Chairmanship of committees of other board	Nil	1	2	3
Shareholdings in Venmax Drugs and pharmaceuticals limited	Nil	Nil	Nil	Nil

Date: August 31, 2026

Place: Hyderabad

By Order of the Board of Directors

Sd/-
Venkata Rao Sadhanala
Managing Director
(DIN: 02906370)

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

ITEM NO. 03

Mr. Venkata Rao Sadhanala was appointed as the Whole-time Director of the Company by the shareholders. To better align his designation with the substantial powers of management exercised by him and given his leadership role in handling the day-to-day business operations, the Board of Directors, at its meeting held on March 11, 2026, proposed to change his designation to Managing Director, as recommended by Nomination & Remuneration Committee subject to the approval of the shareholders.

It is explicitly clarified that the change in designation is by way of **redesignation from Whole-time Director to Managing Director**. His remuneration shall be **₹30,00,000/- (Rupees Thirty Lakhs only) per annum**, subject to the applicable provisions of the Companies Act, 2013, including Sections 197 and 198 read with Schedule V thereto. Except for the change in designation and the remuneration as stated above, there shall be **no other change in the terms and conditions of his appointment**, and his tenure shall continue as per the approved terms of appointment, i.e., for the period from **March 11, 2026 to March 10, 2031**.

The Board recommends the Special Resolution set out at Item No. 03 of the Notice for approval of the Members.

Save and except and his relatives, none of the Directors, Key Managerial Personnel of the Company, or their relatives are concerned or interested, financially or otherwise, in this resolution.

ITEM NO. 04

Mrs. Padmaja Kalyani Sadhanala (DIN: 03096445), was appointed as an Additional Director, Non-Executive Non-Independent Director at the Board of Directors Meeting held on March 30, 2026 as per the recommendation of the Nomination and Remuneration Committee. In terms of Section 161(1) of the Companies Act, 2013, Mrs. Padmaja Kalyani Sadhanala (DIN: 03096445), holds office up to the conclusion of 37th Annual General Meeting of the Company. The Company has received a notice in writing from a shareholder pursuant to the provisions of Section 160 of the Companies Act, 2013 proposing her candidature for appointment as a Director of the Company. Mrs. Padmaja Kalyani Sadhanala (DIN: 03096445), has vast experience in the pharmaceutical industry and possesses the required skills, knowledge and it would be beneficial to the Company if she is on the Board of Directors of the Company. Hence, the Board recommends and seeks approval of the members by passing of the resolution for her appointment as a Non-Executive Non-Independent Director liable to retire by rotation as set out under Item No. 04 of the Notice.

None of the Directors, Key Managerial Personnel of the Company and their relatives, except Mrs. Padmaja Kalyani Sadhanala, the appointee, and Mr. Venkata Rao Sadhanala, Managing Director of the Company, being spouses, are concerned or interested, financially or otherwise, in the resolution set out at Item No. 04 of the Notice. The Board recommends the Ordinary Resolution set out at Item No. 04 of the Notice for approval of the Members.

ITEM NO.05

Mr. Revoor Ramachandra (DIN: 00490051) was appointed as an Additional Director, Non-Executive Independent Director with effect from March 30, 2026 by the Board of Directors on the recommendation of the Nomination and Remuneration Committee and in accordance with the provisions of Section 161(1) of the Companies Act, 2013 and he holds office up to the date of the conclusion of the 37th Annual General Meeting of the Company. The Company has received a notice in writing from a shareholder pursuant to the provisions of Section 160 of the Companies Act, 2013 proposing his candidature for appointment as a Director of the Company. Mr. Revoor Ramachandra (DIN: 00490051) is a Post Graduate with specialization in Production and Materials Management. He has extensive experience in the defence, aerospace and automotive components industries.

Further, the Board of Directors as per the recommendation of the Nomination and Remuneration Committee has proposed to appoint him as an Independent Director for a first term of five (5) consecutive years pursuant to the provisions of Sections 149, 150, 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013 and the Rules made there under on the Company Board and the Company will benefit from his vast experience and expertise, and he will provide valuable strategic guidance in the administration and management of the affairs of the Company. The Board Recommends his appointment.

None of the Directors, Key Managerial Personnel of the Company or their relatives, except Mr. Revoor Ramachandra (DIN: 00490051) is in any way concerned or interested, financially or otherwise, in the resolution set out at Item No. 5 of the Notice. The Board recommends the Special Resolution set out at Item No. 5 of the Notice for approval of the Members.

BOARD'S REPORT

Dear Members,

The Directors have pleasure in presenting the 37th Annual Report of the Company, together with the Audited accounts for the financial year ended 31st March 2026.

Financial Highlights

(Rs. In Lakhs)

Particulars	2025-2026	2024-2025
Sales	802.49	80.73
Other Income	16.04	105.32
Total Income	818.53	186.05
Total Expenses	790.83	187.46
Profit/(Loss) Before Tax	27.70	(1.41)
Current Year Tax	2.88	0.00
Deferred Tax	(0.01)	(0.36)
Profit/(Loss)After Tax	24.82	(1.05)

State of Company Affairs

The Company is engaged in the business of pharmaceutical products, drug intermediates and APIs. During the year under review, the Company achieved a turnover of **Rs. 802.49 Lakhs** as against **Rs. 80.73 Lakhs** during the previous financial year and earned a profit of **Rs. 24.82 Lakhs**. The Board of Directors of the Company is exploring new business opportunities and is confident of expanding and strengthening the Company's business operations in the coming years.

Dividend

In view of the Company's future business plans and the need to conserve resources for business growth and expansion, the Board of Directors has not recommended any Dividend on the Equity Shares of the Company for the Financial Year ended March 31, 2026.

Transfer to Reserves

The Board of Directors has transferred an amount of **₹24.82 Lakhs** to the General Reserve during the year.

Changes in Share Capital

During the year under review, there was no change in the Authorized Share Capital of the Company, which remained at ₹22,00,00,000/- (Rupees Twenty-Two Crores Only) divided into 2,20,00,000 (Two Crore Twenty Lakhs) Equity Shares of ₹10/- (Rupees Ten Only) each.

The paid-up share capital of the Company increased from ₹5,23,89,300/- (Rupees Five Crores Twenty-Three Lakhs Eighty Nine Thousand Three Hundred Only) divided into 52,38,930 (Fifty-Two Lakhs Thirty-Eight Thousand Nine Hundred and Thirty Only) Equity Shares of ₹10/- (Rupees Ten Only) each to ₹11,58,29,300/- (Rupees Eleven Crores Fifty Eight Lakhs Twenty Nine Thousand Three Hundred Only) divided into 1,15,82,930 (One Crore Fifteen Lakhs Eighty Two Thousand Nine Hundred and Thirty Only) Equity Shares of ₹10/- (Rupees Ten Only) each during the year due to the conversion of 63,44,000 Convertible Equity Share Warrants into an equal number of Equity Shares.

The **1,00,25,000 Convertible Equity Share Warrants** were issued on a preferential basis during the previous financial year at an issue price of **₹20/- per warrant**. As on March 31, 2026, **36,81,000 Convertible Equity Share Warrants** remained outstanding and were pending conversion into Equity Shares.

Scheme of Amalgamation

The Board of Directors of the Company at its meeting held on 12th November 2025 approved a Scheme of Amalgamation under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, providing for the amalgamation of Hatri Pharma Private Limited ("Transferor Company") with Venmax Drugs and Pharmaceuticals Limited ("Transferee Company").

Pursuant to Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company submitted the draft Scheme of Amalgamation/Merger to the stock exchanges and successfully received the No Objection Certificate (NOC) from BSE Limited on May 15, 2026.

Following the receipt of the NOC from BSE, the Company filed a First Motion Application before the Honorable National Company Law Tribunal (NCLT), Hyderabad Bench on August 1, 2026 for approval of the draft Scheme of Amalgamation/Merger between Hatri Pharma Private Limited ('Transferor Company') and Venmax Drugs & Pharmaceuticals Limited ('Transferee Company'). The Company is awaiting for registration of the application filed with the Tribunal.

Material Changes and Commitments affecting the Financial Position of the Company which have occurred between 31st March 2026 and August 31, 2026 (Date of the Report)

Out of 36,81,000 Convertible Equity Share Warrants of ₹20/- each outstanding as on March 31, 2026, the Company has received the requisite subscription/call money and converted 29,00,999 warrants into 29,00,999 Equity Shares of ₹10/- each.

The balance 7,80,001 Convertible Equity Share Warrants were forfeited by the Board of Directors due to non-payment of the requisite subscription/call money by the respective warrant holders, after providing the prescribed notice of forfeiture to the warrant holders.

Nature of Business

The Company is engaged in the business of business of pharmaceutical products; drug intermediaries & API's etc. and there has been no change in the nature of Business of the Company.

Public Deposits

During the year under review, the company has not accepted any deposit pursuant to the provisions of Sections 73 and 76 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014.

Annual Return

A copy of the Annual Return for the F.Y 2025-26 pursuant to the sub-section (3) of Section 92 of the Companies Act, 2013 read with Rule 11(1) of the Companies (Management and Administration) Rules, 2014 and forming part of this Report is placed on the website of the Company as per provisions of Section 134(3)

(a) and is available at the following link: www.venmaxdrugs.com

Director's Responsibility Statement

In terms of Section 134 (5) of the Companies Act, 2013, the Directors would like to state that:

- i) In the preparation of the Annual Accounts, the applicable Accounting Standards have been followed.
- ii) The Directors have selected such Accounting Policies and applied them consistently and made judgements and estimates that were prudent so as to give a true and fair view of the state of affairs of the Company at the end of the Financial Year and of the Profit or Loss of the Company for the Year under review.
- iii) The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the Assets of the Company and for preventing and detecting fraud and other irregularities.
- iv) The Directors have prepared the Annual Accounts on a Going Concern basis.
- v) The Directors had laid down Internal Financial Controls to be followed by the Company and that such Internal Financial Controls are adequate and were operating effectively.
- vi) The Directors had devised proper system to ensure compliance with the provisions of all the applicable laws and that such system was adequate and operating effectively.

Directors and Key Managerial Personnel

a. Retirement by Rotation:

As per Section 152 of the Companies Act, 2013 and Articles of Association of the Company, Mr. Swapneswar Mishra (DIN: 09594775), who retires by rotation at the conclusion of this 37th AGM and offers himself for re-appointment in accordance with the provisions of the Companies Act, 2013. The Directors recommend his re- appointment.

b. Composition of Board of Directors

As on March 31, 2026 the Board constitutes the following directors:

Sl. No.	Name of Director	DIN	Designation
1	Mr. Venkata Rao Sadhanala	02906370	Managing Director
2	Mr. Dasi Reddy Rakesh	07112785	Non-Executive, Non-Independent Director
3	Mr. Swapneswar Mishra	09594775	Non-Executive, Non-Independent Director
4	Mr. Gundluru Reddeppa	10419527	Non-Executive, Independent Director
5	Mrs. Padmaja Kalyani Sadhanala	03096445	Non-Executive, Non-Independent Director
6	Revoor Ramachandra	00490051	Non-Executive, Independent Director

c. Changes in Directors and KMP:

During the period ended 31st March 2026 the following changes took place in the Directors and KMP.

Sl. No	Name of Director/KMP	Nature of Change	Date of such change
1	Mrs. Pilli Meena Kumari	Resigned as (Non-Executive Independent Director)	02/09/2025
2	Mrs. Dakshita Jain	Appointed as Additional Director (Non-Executive Independent Director)	02/09/2025
3	Mrs. Dakshita Jain	Resigned as (Non-Executive Independent Director)	24/11/2025
4	Mr. Venkata Rao Sadhanala	Change in designation from Whole Time Director to Managing Director	11/03/2026
5	Mrs. Padmaja Kalyani Sadhanala	Appointed as Additional Director (Non-Executive Non-Independent Director)	30/03/2026
6	Revoor Ramachandra	Appointed as Additional Director (Non-Executive Independent Director)	30/03/2026

d. Changes Subsequent the Financial Year

There were no changes in the composition of the Board of Directors or the Key Managerial Personnel of the Company during the year under review and up to the date of this Directors' Report.

Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

Pursuant to provisions of Section 134 of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 the details of Conservation of Energy, Technology Absorption is attached herewith as '**Annexure-A**'.

Foreign Exchange Earnings and Outgo: During the period under review, there was no Foreign Exchange Earnings or Outflow.

Secretarial Audit

Pursuant to Section 204 and other applicable provisions, if any, of the Companies Act, 2013, Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and Regulation 24A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), other applicable laws/statutory provisions, if any, as amended from time to

time, the Company at its 36th AGM had appointed Kashinath Sahu & Co, Company Secretaries (Firm Registration Number: 4807) were appointed as Secretarial Auditors of the Company for a period of 5 consecutive years commencing from F.Y.2025-26 to F.Y. 2029-30. The Secretarial Audit Report for the F.Y. 2025-26 is annexed herewith as 'Annexure-B'.

During the year under review, there were no qualifications, reservations or adverse remarks reported by Secretarial Auditor under Section 204 of the Companies Act, 2013 in the course of the performance of his duties as Secretarial Auditor.

Corporate Governance and Shareholders Information

In compliance with the Regulation 27 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a separate report on corporate governance along with a certificate from a practicing Company Secretary on its compliance and forms an integral part of this Board's Report as "Annexure- C".

Management Discussion and Analysis

Pursuant to Regulation 34(2)(e) of the SEBI (LODR) Regulations, 2015, Report on Management Discussion and Analysis, is herewith annexed as 'Annexure-D'

Number of Meetings of the Board and Director's Attendance

During the year under review, 16 (Sixteen) Meetings of the Board were convened and held, the details of which are given in the Corporate Governance Report, which forms part of this report. The intervening gap between the Meetings was within the limits prescribed under the Companies Act, 2013.

Formal Annual Evaluation

Pursuant to the provisions of the Companies Act, 2013 and Regulation 25 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board, its Committees and the Directors have carried out annual evaluation / annual performance evaluation, covering various aspects of the Board's functioning such as adequacy of the composition of the Board and its Committees, Board culture, execution and performance of specific duties, obligations and governance. The Directors expressed their satisfaction with the evaluation process.

Declaration from Independent Directors on Annual Basis

The Company has received the Declarations from the Independent Directors of the Company to the effect that they are Meeting the criteria of Independence as provided in sub-section (6) of section 149 of the Act and of sub-rule (1) and sub-rule (2) of the Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014.

In the opinion of the Board, the Independent Directors possess the requisite integrity, expertise and experience (including the proficiency) of the independent directors.

Statutory Auditors

M/s. PPKG & Co, Chartered Accountants (Firm Registration No. 009655S) were appointed as the Statutory Auditors of the Company at the 34th AGM for a term of 5 consecutive financial year starting from 2023-24 to 2027-28 and shall hold office until the conclusion of 39th Annual General Meeting. Your directors recommend their appointment. The said auditors have submitted their report for the financial year 2025-26 without any adverse remark.

Internal Control Systems and their Adequacy

The Company has an in-house Internal Control System, commensurate with the Size, Scale and Complexity of its Operations. The Scope and Authority of the Internal Audit Function is defined in the Internal Audit Manual. To maintain its objectivity and independence, the Internal Audit Function reports to the Chairman of the Audit Committee of the Board and to the Chairman and Management.

The Internal Audit Department monitors and evaluates the efficacy and adequacy of Internal Control System in the Company, its compliance with Operating Systems, Accounting Procedures and Policies at all levels of the Company.

Based on the report of Internal Audit Function, process owners undertake corrective action in their respective areas and thereby strengthen the controls. Significant Audit observations and recommendations along with corrective actions thereon are presented to the Audit Committee of the Board.

Audit Committee

The Board has constituted the Audit Committee as per the provisions of Section 177 of the Companies

Act, 2013 and Regulation 18 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company Secretary of the Company acts as the Secretary of the Audit Committee. The Composition, Attendance, Powers and Role of the Audit Committee are included in Corporate Governance Report. All the recommendation made by the Audit Committee during the period were accepted by the Board of Directors. The Composition, details of meeting held, Attendance, Powers and Role of the Audit Committee are included in Corporate Governance Report.

Nomination and Remuneration Committee

The scope, functions and the terms of reference of the Nomination and Remuneration Committee is in accordance with the Section 178 of the Companies Act, 2013 read with Regulation 19 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Composition, details of meeting held, Attendance, Powers and Role of the nomination & Remuneration Committee are included in Corporate Governance Report.

Stakeholders Relationship Committee

The Composition, Attendance, Powers and Role of the Stakeholders Relationship Committee are included in Corporate Governance Report. The Company Secretary of the Company acts as the Secretary of the Stakeholders' Relationship Committee. The Composition, details of meeting held, Attendance, Powers and Role of the Stakeholders Committee are included in Corporate Governance Report.

Risk Management Committee

The Regulation 21 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to forming of Risk Management Committee, is not applicable to the Company during the Financial Year under review.

Particulars of Loans, Guarantees or Investments under Section 186 of the Companies Act, 2013

The Company has not given any Loans nor provided Guarantee nor made any Investments during the Financial Year 2025-2026, which is beyond the limits as per Section 186 of the Companies Act, 2013.

Contracts or Arrangements with Related Parties under Section 188 (1) of the Companies Act, 2013

The related parties transactions entered by the Company during the period under review was done in the ordinary course of business and on arm's length basis as such the provisions of section 188 of the Companies Act, 2013 and the same is detailed in form AOC - 2 as per Annexure-E to this report.

SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES

The Company do not have any Subsidiary, Joint venture or Associate Company.

Policy on Preservation of the Documents

The Company has formulated a Policy pursuant to Regulation 9 of the Securities Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015 ("Regulations") on Preservation of the Documents of the following type:

- (a) documents whose preservation shall be permanent in nature;
- (b) documents with preservation period of not less than eight years after completion of the relevant transactions

Vigil Mechanism

The Vigil Mechanism/Whistle Blower Policy has been adopted to provide appropriate Avenues to the employees to bring to the attention of the management, the concerns about any unethical behavior by using the mechanism provided in the Policy. In cases related to financial irregularities, including fraud or suspected fraud, the employees may directly approach the Chairman of the Audit Committee of the Company. The web link for the policy is as follows: www.venmaxdrugs.com.

Policy on criteria for determining materiality of events

The Company has adopted a Policy in accordance with the requirements of the Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulations). The Policy is authorizing the mentioned Key Managerial Personnel for the purpose of determining materiality of an event or information of the Company and to ensure that such information is

adequately disseminated in pursuance with the Regulations and to provide an overall governance framework for such determination of materiality.

Policy on directors' appointment, remuneration & other details

The Company's remuneration policy is directed towards rewarding performance based on review of achievements periodically. The remuneration policy is in consonance with the existing industry practice.

The Company's shareholders may refer the Company's website for the detailed Nomination & Remuneration Policy of the Company on the appointment and remuneration of Directors including criteria for determining qualifications, positive attributes, independence of a Director; and other matters provided under sub-section (3) of section 178.

Significant and Material Orders passed by the Regulators or Courts or Tribunals impacting the Going Concerns Status and Company's Operations in future

The Company has not received any Significant or Material Orders passed by any Regulatory Authority, Court or Tribunal which shall impact the Going Concern Status and Company's Operations in future.

Details of Subsidiary Companies, Associates and Joint Venture Companies

The Company does not have any Subsidiary, Associate and Joint Venture Companies during the period under review.

Industrial Relations

Employee relations during the period under review continued to be healthy, cordial and harmonious at all levels and your Company is committed to maintain good relations with the employees. It has taken various steps to improve productivity across the organization.

Business Risk Management

Business Risk Evaluation and Management is an ongoing process within the Organization. The Company has a robust Risk Management Framework to identify, monitor and minimize risks as also identify business opportunities. At present, the Company has not identified any element of risk which may threaten the existence of the Company.

Transfer of Amounts to Investor Education and Protection Fund

Your Company does not have any Unpaid or Unclaimed amounts/Securities lying for a period of seven years. Therefore, there were no Funds/Securities which were required to be transferred to Investor Education and Protection Fund (IEPF).

Particulars of Employees

In terms of Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company does not have any Employee who is employed throughout the Financial Year and in receipt of Remuneration of Rs.120 Lakhs or more, or Employees who are employed for part of the year and in receipt of Rs.8.50 Lakhs or more per month.

Corporate Social Responsibility

The Provisions of Section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility are not applicable to our Company

Maintenance of Cost Records

The Provisions relating to maintenance of Cost Records under Section 148 of Companies Act, 2013 are not applicable to the Company.

Insider Trading Regulations

Based on the requirements under SEBI (Prohibition of Insider Trading) Regulations, 1992 read with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the Code of Conduct for prevention of Insider Trading and the Code for Corporate Disclosures ("Code"), as approved by the Board from time to time, are in force by the Company. The objective of this Code is to protect the interest of Shareholders at large, to prevent misuse of any price sensitive information and to prevent any Insider Trading activity by dealing in Shares of the Company by its Directors, Designated Employees and other Employees. The Company also adopts the concept of Trading Window Closure, to prevent its Directors, Officers, Designated Employees and other Employees from Trading in the Securities of VENMAX DRUGS AND PHARMACEUTICALS LIMITED at the time, when there is Unpublished Price Sensitive Information.

Obligation of Company under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

In order to prevent Sexual Harassment of Women at Workplace as per “The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013” has been notified. Under the said Act, every Company is required to set up an Internal Complaints Committee to look into complaints relating to Sexual Harassment at workplace of any women employee. As required under law, an Internal Compliance Committee has been constituted for reporting and conducting inquiry into the complaints made by the victim on the harassments at the workplace. During the Year under review, no complaint of harassment at the workplace was received by the Committee.

Acknowledgement

Your directors take this opportunity to place on record the valuable co-operation and continuous support extended by its valued business associates, Consultants, Auditors, Suppliers, Customers, Banks / Financial Institutions, Government authorities and the shareholders for their continuously reposed confidence in the Company and look forward to having the same support in all its future endeavors.

Your directors also wish to place on record their sincere appreciation for significant contribution made by the employees at all the levels through their dedication, hard work and commitment, thereby enabling the Company to boost its performance during the year under report.

Date: August 31, 2026

Place: Hyderabad

By Order of the Board of Directors

**Sd/-
Venkata Rao Sadhanala
Managing Director
(DIN: 02906370)**

**Sd/-
Dasi Reddy Rakesh
Director
(DIN: 07112785)**

“ANNEXURE-A”

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN. EXCHANGE

A. Conservation of Energy Power and Fuel Consumption

Particulars	Current Year(2025-26)	Previous Year(2024-25)
1. Electricity (Purchased) Units		
Total Amount (Rs.)	--	--
Rate Per Unit (Rs.)	--	--
2. Electricity (Generated) Units		
Total Amount (Rs.)	--	--
Rate Per Unit (Rs.)	--	--
3. Total Units Consumed		
Units Consumed in Per Lakh Production	--	--

- There were no operations carried out during the period under review. The Company ensures that the Manufacturing Operations are conducted in a manner whereby optimum utilization and maximum possible savings of energy is achieved.
- No specific investment has been made in reduction in energy consumption.
- As the impact of measures taken for conservation and optimum utilization of energy are not quantitative, its impact on cost cannot be stated accurately.

B. Technology Absorption

Company's products are manufactured by using in-house know-how and no outside technology is being used for manufacturing activities. Therefore, no technology absorption is required. The Company constantly strives for maintenance and improvement in quality of its products and entire activities are directed to achieve the aforesaid goal.

C. Foreign Exchange Earning and Outgo

Particulars	Current Year	Previous Years
Earnings	NIL	NIL
Outgo	NIL	NIL

Date: August 31, 2026
Place: Hyderabad

By Order of the Board of Directors

Sd/-
Venkata Rao Sadhanala
Managing Director
(DIN: 02906370)

Sd/-
Dasi Reddy Rakesh
Director
(DIN: 07112785)

“ANNEXURE-B”

FORM NO. MR-3

SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED 31st MARCH, 2026

(Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014)

To

The Members

VENMAX DRUGS AND PHARMACEUTICALS LIMITED

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by VENMAX DRUGS AND PHARMACEUTICALS LIMITED having CIN: L24230TG1988PLC009102 and having registered office at Sy.No.115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Secunderabad, 500009, India (hereinafter called the Company). Secretarial Audit was conducted in accordance with the guidance note issued by the Institute of Company Secretaries of India and in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information, confirmations, clarifications provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on 31st March, 2026, complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the Financial Year ended on 31st March, 2026, according to the provisions of:

- I. The Companies Act, 2013 (the Act) and the rules made there under;
- II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- III. The Depositories Act, 1996 and the Regulations and Byelaws framed there under;
- IV. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings (***Not applicable to the Company during the period of Audit***)
- V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ("SEBI Act"):
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and The Securities Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers (Amendment) Regulations, 2013; (***Not applicable to the Company during the period of Audit***)
 - (b) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015; (***Not applicable to the Company during the period of Audit***);
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; (***Not applicable to the Company during the period of Audit***)
 - (d) Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; (***Not applicable to the Company during the period of Audit***)
 - (e) Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; (***Not applicable to the Company during the period of Audit***)
 - (f) Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; (***Not applicable to the Company during the period of Audit***)

- (g) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; ***(Not applicable to the Company during the period of Audit)***;
- (h) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; ***(Not applicable to the Company during the period of Audit)***
- (i) Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; ***(Not applicable to the Company during the period of Audit)*** and
- (j) Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018; ***(Not applicable to the Company during the period of Audit)***

VI. Other Laws specifically applicable to the Company as per the representations made by the Management include:

- a) Drugs & Cosmetics Act, 1940;
- b) Narcotic Drugs and Psychotropic Substances Act, 1985;
- c) Pharmacy Act, 1948
- d) Hazardous Waste Management Rules, 2016;
- e) National pharmaceutical Policy, 2012
- f) The Factories Act, 1948;
- g) Environ Protection Act, 1996
- h) Employees State Insurance Act, 1948
- i) Employees Provident Fund and Miscellaneous Provisions Act, 1952
- j) The Industrial disputes act, 1947;
- k) The Payment of Wages Act, 1936;
- l) The Minimum Wages Act, 1948;
- m) The Payment of Bonus Act, 1965;
- n) The Payment of Gratuity act, 1972.
- o) The Maternity Benefit Act, 1961.

We have relied on the representations made by the Company, its officers for systems and mechanism framed by the Company for compliances under other Acts, Laws and Regulations applicable to the Company as mentioned above.

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by the Institute of Company Secretaries of India and notified under the Companies Act, 2013;
- (ii) The Listing Agreements entered by the Company with the Stock Exchange(s); ***(Not applicable to the Company during the period of Audit)***

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors/ Committees that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all Directors to schedule the Board Meetings, Agenda and detailed notes on Agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the Meeting.

Majority decisions are carried through while the dissenting member's views, if any, are captured and recorded as part of the Minutes.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable Laws, Rules, Regulations and Guidelines.

We further report that the compliance by the Company of the applicable Financial Laws like Direct and Indirect Tax Laws and maintenance of Financial Records and Books of Accounts has not been reviewed in this Audit since the same have been subject to review by the Statutory Auditors and other designated professionals.

**For Kashinath Sahu & Co
Company Secretaries**

Place: Hyderabad

Date: August 31, 2026

**Sd/-
CS. Kashinath Sahu
Proprietor
FCS: 4790, CP: 4807
UDIN No: F004790H001313911
Peer Review No: 2957/2023**

This report is to be read with our letter of even date, which is annexed as “Annexure - I” and forms an integral part of this report.

“Annexure - (I) to the Secretarial Audit Report”

To
The Members
VENMAX DRUGS AND PHARMACEUTICALS LIMITED

Our report of even date is to be read along with this letter:

- Maintenance of secretarial records is the responsibility of the management of M/s VENMAX DRUGS AND PHARMACEUTICALS LIMITED (“the Company”). Our responsibility is to express an opinion on these secretarial records based on our audit.
- We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices we followed provide a reasonable basis for our opinion.
- We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
- Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
- The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
- The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For Kashinath Sahu & Co
Company Secretaries

Place: Hyderabad
Date: August 31, 2026

Sd/-
CS. Kashinath Sahu
Proprietor
FCS: 4790, CP: 4807
UDIN No: F004790H001313911
Peer Review No: 2957/2023

“ANNEXURE-C”

CORPORATE GOVERNANCE REPORT

The detailed report on corporate governance for the year ended as on 31st March, 2026 under Regulation 27 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is set with following details:

Company’s Philosophy on Code of Governance: -

Your Company’s philosophy on corporate governance envisages adherence to the highest level of transparency, accountability and equity in all areas of its operations and in all interactions with its stakeholders. Your Company is committed to achieve highest standards of corporate governance in its pursuit of excellence, growth and value creation. It believes that all operations must be spearheaded by integrity, transparency and accountability meeting its obligations towards enhanced shareholder value.

The Board of Director of your company are responsible for and committed for good corporate governance practice. The Board plays crucial role in overseeing how the management serves for short- and long-term interests of the shareholders and other stakeholders of the Company.

BOARD OF DIRECTORS:

A. Composition

Our Company’s Board of Directors comprises of 6 Directors, consisting of one Executive Director, Three Non-Executive Director and Two Independent Directors as in accordance Regulation 17 of SEBI (LODR) Regulations, 2015. All the Directors declared that they are not members of more than ten committees in terms of the Listing Agreement and do not act as Chairman of more than five committees across all the companies in which they are Directors. The constitution of the Board during the financial year 2025-26 is as under:

Name of the Director	Executive/ Non-Executive/ Independent	No. of outside Directorships in Public Companies	Membership held in Committee of Directors other Public Companies	Chairmanshi p held in Committee of Directors other Public Companies
Venkata Rao Sadhanala	Managing Director	2	Nil	1
Swapneswar Mishra	Non-Executive, Non-Independent	Nil	Nil	Nil
Dasi Reddy Rakesh	Non-Executive, Non-Independent	2	2	Nil
Gundluru Reddeppa	Non-Executive, Independent	2	2	1
Padmaja Kalyani Sadhanala	Non-Executive, Non-Independent	1	1	1
Revoor Ramachandra	Non-Executive, Independent	1	2	1

B. Board Meetings and Attendance of Director

The Board meets in regular intervals to consider amongst other business, the performance of the Company and the quarterly results apart from the above, additional meetings are held when it is necessary and the gap between two consecutive Board meetings did not exceed 120 days. The Board/ Committee meetings are generally held at the Corporate Office of the Company at Hyderabad. Agenda for each Board /Committee meeting along with explanatory notes are distributed well in advance to the Directors/ Members of the Committee and all the statutory reports and minutes are placed before the Board as per the applicable laws. Every Board member is free to suggest the inclusion of items on the agenda.

During the financial year 2025-26 the Board of Directors of the Company met Sixteen times viz. April 21, 2025, April 26, 2025, May 9, 2025, July 23, 2025, August 16, 2025, August 30, 2025, September 2, 2025, September 16, 2025, November 12, 2025, November 24, 2025, January 21, 2026, February 7, 2026, March 11, 2026, March 23, 2026, March 27, 2026, March 30, 2026.

The Attendance of Directors of the Company at the Board Meetings held during the financial year 2025-26 and previous AGM held on 27.09.2025.

Name of the Directors	No. of Board Meetings held during the tenure	No. of Board meetings attended	Whether attended at last AGM
Mrs. Meena Kumari Pilli	7	7	No
Mrs. Dakshitha Jain	5	5	Yes
Mr. Venkata Rao Sadhanala	16	16	Yes
Mr. Swapneswar Mishra	16	16	Yes
Mr. Dasi Reddy Rakesh	16	16	Yes
Mr. Gundluru Reddeppa	16	16	Yes
Mrs. Padmaja Kalyani	1	1	No
Mr. Revoor Ramachandra	1	1	No

C. Board Agenda

Meetings are governed by a structured agenda. The Board members, in consultation with the Chairman, may take up any matter for consideration of the Board. All major agenda items are backed by comprehensive background information to enable the Board to take informed decisions.

D. Details of Board Meetings held during the Year 2025-26

Date of the Meetings	Board Strength	No. of Directors present
21.04.2025	5	5
26.04.2025	5	5
09.05.2025	5	5
23.07.2025	5	5
16.08.2025	5	5
30.08.2025	5	5
02.09.2025	6	6
16.09.2025	5	5
12.11.2025	5	5
24.11.2025	5	5
21.01.2026	4	4
07.02.2026	4	4
11.03.2026	4	4
23.03.2026	4	4
27.03.2026	4	4
30.03.2026	6	6

E. Code of Conduct

The Board of Directors has laid down Code of Conduct for all Board Members and Senior Management of the Company. The text of the Code of Conduct is uploaded on the website of the Company - www.venmaxdrugs.com The Directors and Senior Management personnel have affirmed compliance

with the Code applicable to them during the year ended 31st March, 2026. The Annual Report of the Company contains a Certificate duly signed by the Managing Director in this regard.

- F. Shares held by non- executive Directors Non-executive & Non-Independent Director holds Nil shares in the Company.**

BOARD COMMITTEES:

The Board Committees play crucial role in corporate governance and have been constituted to deal with specific areas and the periodical meetings have been held to review the matters and the minutes of the same were placed before the Board.

Audit Committee:

Terms of reference:

The terms of reference of Audit Committee encompass the requirements of Section 177 of Companies Act, 2013 and Regulation 18 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 of the Listing Agreement.

The terms of reference inter-alia include:

1. Oversee the company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible.
2. Recommending to the Board, the appointment and removal of external auditor and fixation of audit fees and also approval of payment for any other services.
3. Reviewing, with the management, the annual financial statements before submission to the Board focusing primarily on:
 - Any changes in accounting policies and practices.
 - Major accounting entries involving estimates based on the exercise of judgment by management.
 - Significant adjustments arising out of audit.
 - The going concern assumption.
 - Compliance with accounting standards.
 - Compliance with stock exchange and other legal requirements relating to financial statements.
4. Reviewing, with the management, the quarterly financial statements before submission to the board for approval.
5. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit.
6. Discussion with internal auditors any significant findings and follow up thereon.
7. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board.
8. Discussion with external auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern.
9. To Review in Company's financial and risk management policies.

Mandate, Role and Responsibilities of the Audit Committee:

As specified under the Companies Act 2013, and the Rules made thereunder, Listing Agreement, SEBI Regulations and regulatory requirements that may come into force from time to time; and as may be mandated by the Board of Directors from time to time.

Composition of the Audit Committee as on March 31, 2026:

1. Mr. Gundluru Reddeppa - Independent Director & Chairperson
2. Mr. Revoor Ramachandra - Independent Director & Member
3. Mr. Swapneswar Misra - Non-Executive and Non-Independent Director & Member

Meetings and Attendance:

Four Audit Committee Meetings were held during the year ended 31st March, 2026. The maximum time gap between any of the two meetings was not more than four months.

Audit Committee Meetings held during the year 2025-26 and attendance details:

Date of the Meeting	Committee Strength	No. of Directors present
09.05.2025	3	3
23.07.2025	3	3
12.11.2025	3	3
07.02.2026	3	3

Managing Director, Chief Financial Officer were invitees for the Audit Committee Meetings. The Statutory Auditors of the Company were invited to join the Audit Committee in the meetings for discussing the financial results, financial statements and the Annual/Audited Accounts before placing it to the Board of Directors.

NOMINATION AND REMUNERATION COMMITTEE:

The terms of reference of Nomination & Remuneration Committee encompass the requirements of Section 178 of Companies Act, 2013 and Regulation 19 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.

The key role of this Committee is as follows:

- Provide oversight on Strategic Human Capital issues.
- Search for, evaluate shortlist and recommend the incumbent for the position of Managing Director and other Directors and their engagement terms to the Board.
- Evaluate and approve for appointment candidates recommended by Managing Directors for key senior positions.
- Review the Succession Plan for Critical Positions and suggest actions.
- Have the responsibility for setting the remuneration for the Managing Director and Whole Time Directors. Review remuneration for the Key Managerial Personnel of the Company. Remuneration in this context will include salary, and performance based variable component and any compensation payments, such as retrial benefits or stock options.

Mandate, Role and Responsibilities of the Nomination and Remuneration Committee:

As specified under the Companies Act 2013, Rules under the Companies Act 2013, Listing Agreement, SEBI Regulations and regulatory requirements that may come into force from time to time; and as may be mandated by the Board of Directors from time to time.

Composition of the Nomination and Remuneration Committee as on March 31, 2026:

1. Mr. Gundluru Reddeppa - Independent Director & Chairperson
2. Mr. Revoor Ramachandra - Independent Director & Member
3. Mr. Dasi Reddy Rakesh - Non-Executive and Non-Independent Director & Member

Remuneration policy -

i) For Managing Director

The total remuneration pursuant to shareholders approval consists of:

- a fixed component - consisting of salary and perquisites
- a variable component by way commission as determined by the Board/Nomination and Remuneration Committee within the limits approved by the shareholders

ii) For Non-executive Directors

Criteria for making payments to Non-Executive Director will be decided by the Board. It can be on the basis of-

- Contribution during the meeting
- Active Participation in strategic decision making

Nomination and Remuneration Committee Meetings held during the year 2025-26 and attendance details:

Date of the Meeting	Committee Strength	No. of Directors present
26.04.2025	3	3
30.03.2026	3	3

STAKEHOLDERS RELATIONSHIP COMMITTEE:

The Stakeholders Relationship Committee currently comprises of the following Directors:

1. Mr. Swapneswar Mishra - Independent Director & Chairperson
2. Mr. Gundluru Reddeppa - Independent Director & Member
3. Mr. Dasi Reddy Rakesh - Non-Executive and Non-Independent Director & Member

The Stakeholders Relationship Committee specifically looks into redressing of shareholders/ investors complaints in matters such as transfer of shares, non-receipt of declared dividends and ensure expeditious share transfer process.

Number of Shareholders Complaints received during the year	0
Solved to the satisfaction of the shareholders	0
Number of pending Complaints	0

Stakeholders Relationship Committee Meetings held during the year 2025-26 and attendance details:

Date of the Meeting	Committee Strength	No. of Directors present
23.07.2025	3	3
30.03.2026	3	3

Independent Directors Meeting held during the year 2025-26 and attendance details

Date of the Meeting	No. of Directors present
30.03.2026	2

GENERAL BODY MEETINGS:

Location and time where the last three Annual General Meetings were held is as under:

Financial Year	Date	Location of the Meeting	Time
2022-23	06.09.2023	J.S. Krishnamurthy Hall, FATPCCI Building, Red Hills, Hyderabad, 500004	10.30 A.M
2023-24	21.09.2024	Through Video Conferencing/Other Audio Visual	04.30 P.M
2024-25	27.09.2025	Through Video Conferencing/Other Audio Visual	10.00 A.M

DISCLOSURES:

a. Basis of Related Party transactions:

There were no significant related party transactions during the year under review that may prejudice the interest of the Company. However, a statement of summary of transactions with related parties along with all material individual transactions was placed before the Audit Committee along with management justification.

b. Disclosure of accounting treatment:

The Company follows accounting standards notified under the Companies Act, 2013 in preparation of financial statements and have not been deviated from the current accounting Standards.

c. Risk management:

The Company laid down adequate procedures to inform Board members regarding risk assessment and mitigation.

d. Whistle Blower Policy and Vigil mechanism:

In compliance with the non-mandatory provisions of Listing Regulations the Company proposed to establish vigil mechanism to provide adequate safeguards against victimization persons who use such mechanism and to provide direct access to the Chairman of the Audit Committee in cases such as concerns about unethical behavior, frauds and other grievances.

e. Compliance with the Mandatory requirements and Implementation of the Non-Mandatory requirements:

The Company has complied with the mandatory requirements of the Corporate Governance Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and for the same a certificate from Statutory Auditors was obtained and attached herewith. The Company has not implemented the non-mandatory requirements enlisted by way of annexure to Regulation 27 of the Listing Regulations.

f. Management Discussion and Analysis Report:

The Management Discussion and analysis report is appended to this report.

g. Compensation to Non-executive Directors:

During the period the Company has not paid any compensation to Non-executive Directors including setting fee.

h. Means of communication

The Quarterly, half-yearly, annual financial results, notices as well as proceedings of the Annual General Meeting are communicated to the stock exchanges immediately after the conclusion of the respective meetings. The results are published in English and Telugu newspapers in district where the registered office of the Company situated.

i. Certification on Corporate Governance

As required by Regulation 27 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a certificate issued by M/s. Kashinath Sahu & Co., Company Secretaries, Hyderabad, Secretarial Auditors of the Company, regarding compliance of conditions of Corporate Governance is annexed to this report.

GENERAL SHAREHOLDER INFORMATION:**a) Annual General Meeting:**DATE : 26th September, 2026

TIME : 12.30 P.M

VENUE : Through Video Conferencing

b) Tentative calendar for financial year 2025-26:

First Quarter results - Within 45 days of end of quarter.

Second Quarter results - Within 45 days of end of quarter.

Third quarter results - Within 45 days of end of quarter.

Fourth quarter results - Within 60 days of end of quarter.

c) Book Closure Dates:From 18th September, 2026 to 26th September, 2026 (both days inclusive).**d) Listing of equity shares & stock code:**

The equity shares of the company are listed at Bombay Stock Exchange Limited., Mumbai, 1st Floor, New Trading Ring, P.J. Towers, Dalal Street, Fort, Mumbai - 400 001 and Stock Code 505797.

e) ISIN No: INE154G01022**f) Registrar and Transfer Agents:****CIL Securities Limited**

214, Raghavaratna Towers, Chirag Ali Lane, Hyderabad, 500001

g) Categories wise shareholding as on 31st March, 2026:

Category	Holding as on 31.03.2026
Promoter and Promoter Group	1212025
Bodies Corporate	1432365
Central/State Government(s)	0
Financial Institutions/Banks	0
Foreign Bodies Corporate	0
Foreign Institutional Investors	0
Insurance Companies	0
Mutual Funds/UTI	0
Non-Residential Individuals	262243
Public	8676297
Trust	0
Total	11582930

h) Declaration

As required under Schedule V(D) of SEBI (LODR) Rules 2015, it is hereby affirmed that all the Board Members and Senior Management Personnel have complied with the code of conduct of the Company. It is also confirmed that code of conduct has already been posted on the website of the Company.

i) The Disclosure of the compliance with Corporate Governance requirements specified in regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 are as follows:

Regulation	Particulars of Regulations	
17	Board of Directors	Yes
18	Audit Committee	Yes
19	Nomination and Remuneration Committee	Yes
20	Stakeholder Relationship Committee	Yes
21	Risk Management Committee	NA
22	Vigil Mechanism	Yes
23	Related Party Transactions	Yes
24	Corporate Governance requirements with respect to subsidiary listed entity	NA
25	Obligations with respect to Independent Director	Yes
26	Obligations with respect to Directors and Senior Management	Yes
27	Other Corporate Governance requirements	Yes
46 (2) (b) to (i)	Website	Yes

j) Code of Conduct:

The Board has laid down a Code of Conduct covering the ethical requirements to be complied with covering all the Board members and all employees of the Company. An affirmation of compliance with the code is received from them on an annual basis.

k) CEO and CFO Certification:

The Managing Director and the CFO have given a Certificate to the Board as contemplated in Schedule-V of the Securities and Exchange Board of India. (Listing Obligations and Disclosure Requirements) Regulations, 2015 and is separately annexed.

CODE OF CONDUCT DECLARATION

As provided under Schedule-V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors and the Senior Management Personnel have confirmed compliance with the Code of Conduct and Ethics for the financial year ended 31st March 2026.

Address for Correspondence:

Venmax Drugs and Pharmaceuticals Limited

CIN: L24230TG1988PLC009102

Sy.No.115, Brig Sayeed Road, Hanumanji Colony,
Bowenpally, Picket, Secunderabad,
Telangana, 500009.

E-mail: Venmaxdrugs@gmail.com

Website: www.venmaxdrugs.com

Date: August 31, 2026

Place: Hyderabad

By Order of the Board of Directors

Sd/-
Venkata Rao Sadhanala
Managing Director
(DIN: 02906370)

Sd/-
Dasi Reddy Rakesh
Director
(DIN: 07112785)

DECLARATION REGARDING COMPLIANCE BY BOARD MEMBERS AND SENIOR MANAGEMENT PERSONNEL WITH COMPANY'S CODE OF CONDUCT

In terms of SEBI (LODR) Regulations, 2015, I hereby confirm that all the Board members and Senior Management Personnel of the Company have affirmed compliance with the respective Codes of Conduct, as applicable to them for the year ended 31st March, 2026.

Date: August 31, 2026
Place: Hyderabad

By Order of the Board of Directors

Sd/-
Venkata Rao Sadhanala
Managing Director
(DIN: 02906370)

Sd/-
Dasi Reddy Rakesh
Director
(DIN: 07112785)

CERTIFICATE OF COMPLIANCE OF CONDITIONS OF CORPORATE GOVERNANCE

To

The Members,
VENMAX DRUGS AND PHARMACEUTICALS LIMITED

We have examined the compliance of conditions of Corporate Governance by VENMAX DRUGS AND PHARMACEUTICALS LIMITED ("the Company"), for the year ended on March 31, 2026, as stipulated in Regulation 15(2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) for the period 1st April 2025 to 31st March 2026.

The compliance of conditions of Corporate Governance is the responsibility of Management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the Financial Statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us by the Directors, officers and the management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above-mentioned Listing Regulations.

We further state that, such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

**For Kashinath Sahu & Co
Company Secretaries**

**Place: Hyderabad
Date: August 31, 2026**

**Sd/-
CS. Kashinath Sahu
Proprietor
FCS: 4790, CP: 4807
UDIN No: F004790H001313955
Peer Review No: 2957/2023**

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10) (i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members,
VENMAX DRUGS AND PHARMACEUTICALS LIMITED

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of VENMAX DRUGS AND PHARMACEUTICALS LIMITED having CIN: L24230TG1988PLC009102 having registered office at Sy.No.115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Secunderabad, 500009, Telangana, India (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V, Para-C, Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in, as considered necessary and explanations furnished to us by the Company & its officers, We hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2026 have been debarred or disqualified from being appointed or continuing as Directors of Companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

Sl. No.	Name of Director	DIN	Designation	Date of Appointment in the Company
1	*Mr. Venkata Rao Sadhanala	02906370	Managing Director	01.10.2024
2	Mr. Dasi Reddy Rakesh	07112785	Non-Executive, Non-Independent Director	22.08.2024
3	Mr. Swapneswar Mishra	09594775	Non-Executive, Non-Independent Director	16.01.2024
4	Mrs. Gundluru Reddeppa	10419527	Non-Executive, Independent Director	22.08.2024
5	Mrs. Padmaja Kalyani Sadhanala	03096445	Non-Executive, Non-Independent Director	30.03.2026
6	Mr. Revoor Ramachandra	00490051	Non-Executive, Independent Director	30.03.2026

**Mr. Venkata Rao Sadhanala Appointed as a Managing Director w.e.f. March 11, 2026.*

**During the Financial Year 2025-2026 Mrs. Dakshitha Jain appointed as independent director on September 2, 2025 and resigned on November 24, 2025.*

Ensuring the eligibility for the appointment/continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is only to express an opinion on this as per our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

**For Kashinath Sahu & Co
Company Secretaries**

**Place: Hyderabad
Date: August 31, 2026**

**Sd/-
CS. Kashinath Sahu
Proprietor
FCS: 4790, CP: 4807
UDIN No: F004790H001314001
Peer Review No: 2957/2023**

MANAGING DIRECTOR / CFO CERTIFICATION

CERTIFICATE PURSUANT TO REGULATION 17(8) AND 33(2) OF THE LISTING REGULATIONS

- A. We have reviewed financial statements and cash flow statements for the financial year 2025-2026, and that to the best of our knowledge and belief:
1. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 2. These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- B. There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.
- C. We accept responsibility for establishing and maintaining internal controls for financial reporting and we have evaluated the effectiveness of internal control systems of the company pertaining to financial reporting, and deficiencies in the design and operation of such internal controls, if any, of which we are aware, have been disclosed to the Auditors and Audit Committee and steps have been taken to rectify these deficiencies.
- D. We have indicated to the Auditors and the Audit committee that during the year
1. there were no significant changes in internal controls over financial reporting,
 2. there were no significant changes in accounting policies during the year requiring disclosure in the notes to the financial statements, and
 3. we are not aware of any instances of significant fraud with involvement therein of the management or any employee having a significant role in the Company's internal control system over financial reporting.

Date: August 31, 2026
Place: Hyderabad

By Order of the Board of Directors

Sd/-
Venkata Rao Sadhanala
Managing Director
(DIN: 02906370)

Sd/-
Dasi Reddy Rakesh
Director
(DIN: 07112785)

“ANNEXURE-D”

MANAGEMENT DISCUSSION AND ANALYSIS

a) Outlook:

The Directors are exploring possibilities of alternative business proposals.

b) Segment wise Performance:

The Company operates in a single segment during the period.

c) Internal control systems and their adequacy:

The Company has an in-house Internal Control System, commensurate with the Size, Scale and Complexity of its Operations.

d) Financial performance with respect to operations:

During the year, the Company has achieved Turnover of Rs. 802.49 Lakhs and earned a PAT of **Rs. 24.82 Lakhs.**

Annexure - E

FORM NO. AOC.2

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

1. Details of contracts or arrangements or transactions not at arm's length basis - Not Applicable

- Name(s) of the related party and nature of relationship
- Nature of contracts/arrangements/transactions
- Duration of the contracts/arrangements/transactions
- Salient terms of the contracts or arrangements or transactions including the value, if any
- Justification for entering into such contracts or arrangements or transactions
- date(s) of approval by the Board
- Amount paid as advances, if any:
- Date on which the special resolution was passed in general meeting as required under first proviso to section 188

2. Details of material contracts or arrangement or transactions at arm's length basis - as below

Name(s) of the related party and nature of relationship	Venkata Rao Sadhanala Managing Director of the Company
Nature of contracts/ arrangements/ transactions	Unsecured Loan
Duration of the contracts/ arrangements/ transactions	
Salient terms of the contracts or arrangements or transactions including the value, if any	7 Lakhs
Date(s) of approval by the Board, if any	09.05.2025
Amount paid as advances, if any	NA

Name(s) of the related party and nature of relationship	Somani Herbs and Agro Products India Pvt Ltd Common Directorship
Nature of contracts/ arrangements/ transactions	Unsecured Loan
Duration of the contracts/ arrangements/ transactions	
Salient terms of the contracts or arrangements or transactions including the value, if any	2.96 Lakhs
Date(s) of approval by the Board, if any	09.05.2025
Amount paid as advances, if any	NA

Name(s) of the related party and nature of relationship	Blue Nile Capital advisory Limited Common Directorship
Nature of contracts/ arrangements/ transactions	Unsecured Loan
Duration of the contracts/ arrangements/ transactions	
Salient terms of the contracts or arrangements or transactions including the value, if any	562.55 Lakhs
Date(s) of approval by the Board, if any	09.05.2025
Amount paid as advances, if any	NA

Name(s) of the related party and nature of relationship	Omega Ag Seeds Punjab Limited Common Directorship
Nature of contracts/ arrangements/ transactions	Unsecured Loan
Duration of the contracts/ arrangements/ transactions	
Salient terms of the contracts or arrangements or transactions including the value, if any	2.85 Lakhs
Date(s) of approval by the Board, if any	23.07.2025
Amount paid as advances, if any	NA

INDEPENDENT AUDITOR'S REPORT

**TO
THE MEMBERS OF
VENMAX DRUGS AND PHARMACEUTICALS LIMITED.
HYDERABAD**

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying Standalone Financial Statements of M/s **VENMAX DRUGS AND PHARMACEUTICALS LIMITED** ("the Company"), which comprise the balance sheet as at 31st March, 2026, and the statement of profit and loss, Statement of changes in Equity and Statement of cash flow for the year ended, and notes to the standalone Financial Statements, including a summary of significant accounting policies and other explanatory information [hereinafter referred to as "Standalone Financial Statements"].

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act and accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and its Losses, (changes in equity) and its cash flow statement for the year ended on that date.

Basis for Opinion

We conducted our audit of the Standalone Financial Statements in accordance with the Standards on Auditing (SA's) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Companies Act, 2013 and the Rules defined thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

We draw attention to Note 37 and 38 to the accompanying financial statements, which describes the proposed Scheme of Amalgamation of Hatri Pharma Private Limited ("Transferor Company") with Venmax Drugs and Pharmaceuticals Limited ("Transferee Company") under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.

As disclosed therein, subsequent to the reporting period, the Company received the NOC (No Objection Certificate) from BSE Limited vide its letter dated 15 May 2026 in respect of the proposed Scheme. The Scheme is presently pending approval of the National Company Law Tribunal (NCLT) and other requisite statutory and regulatory approvals. Pending the Scheme becoming effective, no effect of the proposed amalgamation has been given in the accompanying financial statements.

Our opinion is not modified in respect of this matter.

"Information Other than the Financial Statements and Auditor's Report Thereon"

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Director's report but does not include the Financial Statements and our auditor's report thereon.

Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Key Audit Matters

Key Audit Matters are those matter that, in our professional judgement, were of most significance in our audit of the Standalone Financial Statements of the current period. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. During the year under consideration, we have no Key Audit Matters to report.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Standalone Financial Statements that give a true and fair view of the financial position, State of affairs, Profit/loss (including other comprehensive income) Change in Equity and Cash Flow of the company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified under section 133 of the Act, read with Rules defined there under. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Statements, as a whole, are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform Audit Procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system with reference to the Standalone Financial Statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of the Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the Financial Statements, including the disclosures, and whether the Standalone Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Materiality is the magnitude of misstatements in the Standalone Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in:
 1. Planning the scope of our audit work and in evaluating the results of our work; and
 2. To evaluate the effect of any identified misstatements in the Standalone Financial Statements.
- We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
- We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure-A" statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company, so far as it appears from our examination of those books.
 - (c) The Balance Sheet, the Statement of Profit and Loss and cash flow statement dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - (e) On the basis of the written representations received from the directors as on 31st March, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164(2) of the Act.
 - (f) According to information and explanations given to us together with our audit examination, reporting with respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls we give in Annexure-B to the extent applicable.
 - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- i. The Company does not have any pending litigations which would impact its financial position.
- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv. a. The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- b. The management has represented, that, to the best of its knowledge and belief, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- c. Based on such audit procedures that the auditor has considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.
- v. No Dividend has been declared or paid during the year by the company, hence provisions of section 123 of the Companies Act, 2013, are not applicable.
- vi. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software's. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

FOR PPKG AND CO
Chartered Accountants
F.R.No. 09655S

Sd/-
GIRDHARI LAL TOSHNIWAL
(PARTNER)
M No. 205140
UDIN NO- 26205140VEQLOS2924

Place: Hyderabad
Date: 14/05/2026

Annexure – A to the Independent Auditor’s Report of even date to the Members of M/s Venmax Drugs and Pharmaceuticals Limited, on the Financial Statements for the Year ended March 31, 2026.

Based on the audit procedures performed for the purpose of reporting a true and fair view on the Financial Statements of the Company and taking into consideration the information and explanations given to us and the Books of Accounts and other records examined by us in the normal course of Audit, and to the best of our knowledge and belief, we report that:

- i)
 - a. The Company has maintained proper records showing full particulars, including quantitative details and situation of Fixed Assets,
 - b. The Company has a regular program of physical verification of its Fixed Assets under which Fixed Assets are verified in a phased manner over a period for which we have received the certificate of confirmation from the Management.
 - c. The company does not have any Immovable Properties (which are included under the head ‘Property, Plant and Equipment’) held in the name of the Company.
 - d. The Company has not revalued any of its Property, Plant and Equipment’s during the year.
 - e. As per the information given to us there are no proceedings initiated or pending against the Company for holding any Benami Property under the Benami Transactions (Prohibition) Act, 1988 and Rules made there under.
- (ii)
 - a. Management has conducted physical verification of Inventory at regular intervals of time.
 - b. The Company has not availed any Financial Assistance from any Bank or Financial Institutions.
- (iii) The Company has granted Loans to company as listed below:
 - Blue Nile Capital Advisory Limited- Rs 466 Lakhs
 - Omega AG Seeds Punjab Limited- Rs 2.85 Lakhs
 - Santha Ghosh- Rs 78 Lakhs
 - Vidhata Life Science - Rs 36.53 Lakhs
 - Vineet Life Sciences Limited- Rs 55.05 Lakhs
- (iv) The Company has not entered into any transaction covered under Section 185 and Section 186 of the Act in respect of Guarantees and Security.
- (v) In our opinion, the Company has not accepted any Deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable.
- (vi) As informed to us that the provisions of Section 148 are not applicable to the Company.
- (vii) (a) In our opinion, the Company has been regular in depositing undisputed statutory dues, including Goods and Services Tax, Income Tax, Sales Tax, Duty of Custom, Cess and other material statutory dues applicable to it with the appropriate authorities. There were no undisputed amounts payable in respect of Goods and Service Tax, Income Tax, Sales Tax, duty of Custom, duty of Excise, Cess and other material statutory dues in arrears as at March 31, 2026 for a period of more than six months from the date they become payable. However as per the information provided by the management, Provident Fund and Employees’ State Insurance is not applicable to the company for the current year and even PT is not paid for the company during the year.
- (b) There is Dues outstanding in respect of Income Tax as shown in the Income Tax portal as on 31/03/2026 and as said by the management no due in respect of Sales Tax, Service Tax, Duty of Customs on account of disputes.

- (c) According to the information and explanations given to us, the dues in respect of Sales Tax, Income Tax, Custom Duties, Wealth Tax, Excise Duty and Cess that have been deposited with the appropriate authorities except in cases where there is a dispute.
- (viii) All the transactions recorded in the books of account have been disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961). There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as Income during the year in the Tax Assessments under the Income Tax Act, 1961 (43 of 1961).
- (ix) The company does not have any borrowing from Banks or any Financial Institution as on the reporting date; accordingly, this clause is not applicable.
- (x) The Company has not raised the funds by way of Initial Public Offer during the reporting period. But during the year the company has increased its Paid-up capital from 523.89 lakhs to 1,158.29 lakhs during the FY 2025-2026 for which details have been mentioned in the Financials.
- (xi)
- a. According to the information and explanations given to us, no material fraud by the Company or by its officers or employees has been noticed or reported during the course of Audit.
 - b. No Report under sub-section (12) of section 143 of the Companies Act has been filed by the Auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
 - c. No Whistle Blowers Complaints were received during the year under review. As represented to us by the Management, no Whistle Blowers Complaints were received during the year under review.
- (xii) In our opinion, the Company is not a Nidhi Company, and accordingly, provisions of Clause 3(xii) of the Order are not applicable.
- (xiii) In our opinion, the Company is in compliance with Sections 177 and 188 of the Companies Act, 2013, with respect to applicable transactions with related parties, and the requisite details have been disclosed in the Financial Statements.
- (xiv) As per the information provided to us, the company does not have an adequate Internal Audit System.
- (xv) In our opinion, the Company has not entered in any non-cash transactions with the Directors or persons connected with them covered under Section 192 of the Act. Accordingly, the provisions of Clause 3(xv) of the order are not applicable.
- (xvi)
- a. According to the information and explanation given to us, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934 and the Company has not conducted any NBFC Company during the year.
 - b. The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934.
- (xvii) The Company has not incurred any cash losses during the current Financial Year and incurred cash losses of ₹0.05 lakhs during the immediately preceding Financial Year.
- (xviii) There has been no resignation of Statutory Auditors during the Financial year 2025-26.
- (xix) On the basis of the Financial Ratios, ageing and expected dates of realization of Financial Assets and payment of Financial Liabilities, other information accompanying the Financial Statements, the Auditor's knowledge of the Board of Directors and the Management's plans, the Auditor is of the opinion that no material uncertainty exists as on the date of the Audit Report and that the Company is capable of meeting its Liabilities existing at the Date of Balance Sheet, as and when they fall due within a period of one year from the Balance Sheet Date. We however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- (xx) The Company is not liable to contribute under Section 135 of the Companies Act, 2013. Accordingly, the provisions of Clause 3(xx) of the order are not applicable.
- (xxi) In our opinion and according to the information and explanations given to us, Company does not have any subsidiaries; associates and joint venture. Therefore, this clause is not applicable.

For PPKG & Co
Chartered Accountants
Firm's Registration No. 09655S

Sd/-
Girdhari Lal Toshniwal
Partner
Membership No. 205140
UDIN: 26205140VEQLOS2924

Date: 14/05/2026
Place: Hyderabad

ANNEXURE - B TO THE AUDITORS' REPORT

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of M/s **VENMAX DRUGS AND PHARMACEUTICALS LIMITED**. ("The Company") as of 31 March 2026 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India

For PPKG AND CO
Chartered Accountants
F.R.No. 09655S

Sd/-
GIRDHARI LAL TOSHNIWAL
(Partner)
M.No -205140
UDIN: 26205140VEQLOS2924

Place: HYDERABAD
Date: 14/05/2026

BALANCE SHEET AS AT 31st MARCH 2026

(Amount in Lakhs)

Particulars	Notes	As at 31 March 2026, Audited	As at 31 March 2025, Audited
I.ASSETS			
(1) Non-Current Assets			
(a) Property, Plant and Equipment	3	3.65	4.05
(b) Capital Work-In-Progress			
(c) Intangible Assets			
(d) Financial Assets			
(i) Non-Current Investments			
(ii) Trade and Other Receivables			
(iii) Long Term Loans and Advances			
(d) Deferred Tax Assets (Net)			
(e) Other Non-Current Assets			
Non-Current Assets		3.65	4.05
(2) Current Assets			
(a) Inventories	4	99.88	5.75
(b) Financial Assets			
(i) Investments			
(ii) Trade and Other Receivables	5	143.00	95.26
(iii) Cash and Cash Equivalents	6	122.36	248.24
(iv) Other Financial Assets	7	734.97	161.00
(c) Other Current Assets	8	516.14	2.67
Current Assets		1616.36	512.91
Total Assets		1620.02	516.96
I. EQUITY AND LIABILITIES			
(1) Equity			
(a) Share Capital	9	1158.29	523.89
(b) Other Equity	10	253.33	(82.70)
Equity		1411.62	441.19
(2) Non-Current Liabilities			
(a) Financial Liabilities			
(i) Long Term Borrowings	11(a)	4.96	4.96
(b) Provisions			
(c) Deferred Tax Liabilities (Net)	12	0.10	0.10
(d) Other Non-current Liabilities			
Non-Current Liabilities		5.06	5.06
(3) Current Liabilities			
(a) Financial Liabilities			
- Short term Borrowings	11(b)	28.13	0.00
-Other Financial Liabilities	13	1.81	0.85
(i) Trade Payables			
Micro and small enterprises			
Other than micro and small enterprises	14	167.73	62.87

(b) Short Term Provisions	15	3.81	0.70
(c) Other Current Liabilities	16	1.86	6.29
Current Liabilities		203.3	70.7
Total Liabilities		1620.02	516.96

As per Our report of even date
For PPKG & Co
Chartered Accountants,
F.R.No.096555

Sd/-
Girdhari Toshniwal
PARTNER
Membership No: 205140
UDIN:26205140VEQLOS2924

Place: HYDERABAD
Date: 14/05/2026

For and on behalf of the Board of Directors of
Venmax Drugs and Pharmaceuticals Limited

Sd/-
Dasi Reddy Rakesh
Director
DIN: 07112785

Sd/-
K. Sai Baba
Chief Financial Officer

Sd/-
Venkata Rao Sadhanala
Managing Director
DIN: 02906370

Sd/-
Priyanka Agarwal
Company Secretary &
Compliance Officer

Statement of Profit & Loss for the year ended 31st March, 2026

(Amount in Lakhs)

Particulars	Notes	Year ended 31st March, 2026, Audited	Year ended 31st March, 2025, Audited
Revenue from operations	17	802.49	80.73
Other income	18	16.04	105.32
Total Revenue		818.53	186.05
Expenses			
Cost of materials consumed			
Purchases of Stock-in-Trade	19	822.27	85.21
Changes in inventories of finished goods		(94.13)	(5.75)
Employee benefits expense	20	19.67	4.04
Finance costs		-	-
Depreciation and amortization expense	21	0.40	0.64
Other expenses	22	42.64	103.31
Total expenses		790.83	187.46
Profit before exceptional, extraordinary and prior period items and tax		27.70	(1.41)
Exceptional items			
Profit before extraordinary and prior period items and tax		27.70	(1.41)
Extraordinary Items			
Profit before prior period items and tax		27.70	(1.41)
Prior Period Items			
Profit before tax		27.70	(1.41)
Tax expense:			
Current tax	23	2.88	-
Deferred tax		(0.01)	(0.36)
Profit/(loss) for the period from continuing operations		24.82	(1.05)
Profit/(loss) from discontinuing operations			
Tax expense of discontinuing operations			
Profit/(loss) from Discontinuing operations (after tax)			
Profit/(loss) for the period		24.82	(1.05)
Earnings per equity share:	24		
Basic		0.21	(0.02)
Diluted		0.21	(0.02)

As per Our report of even date
For PPKG & Co
Chartered Accountants,
F.R.No.09655S

Sd/-
Girdhari Toshniwal
PARTNER
Membership No: 205140
UDIN:26205140VEQLOS2924

Place: HYDERABAD
Date: 14/05/2026

For and on behalf of the Board of Directors of
Venmax Drugs and Pharmaceuticals Limited

Sd/-
Dasi Reddy Rakesh
Director
DIN: 07112785

Sd/-
K. Sai Baba
Chief Financial Officer

Sd/-
Venkata Rao Sadhanala
Managing Director
DIN: 02906370

Sd/-
Priyanka Agarwal
Company Secretary &
Compliance Officer

CASH FLOW STATEMENT ANNEXED TO THE BALANCE SHEET

(Amount In Lakhs)

PARTICULARS	As at Mar 31, 2026 Audited	As at Mar 31, 2025 Audited
A) CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit as per Profit & Loss A/c	27.70	(1.41)
Adjustment for:		
Depreciation	0.40	0.64
Other comprehensive income	-	-
Loss on Sale / Discard of Intangible Assets (Net)	-	1.89
Net Operating Profit Before Working Capital	28.10	1.12
Changes		
Adjustment for:		
Trade & Other Receivables	(47.75)	(95.26)
Changes in inventory	(94.13)	(5.75)
Other Current Assets	(513.48)	(1.36)
Trade Payables	104.86	52.53
Other Financial liabilities	0.96	(10.82)
Other current liabilities	(4.42)	(6.24)
Provisions	3.11	(2.24)
Short Term Loans and Advances	(573.97)	(161.00)
Net Cash from Operating Activities	(1096.74)	(229.02)
Direct taxes paid	2.87	0
Net Cash from Operating Activities	(1099.61)	(229.02)
B) CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	-	-
Sale of Fixed assets	-	-
Net Cash from Investing Activities	-	-
C) CASH FLOW FROM FINANCING ACTIVITIES		
Share warrants application money pending allotment	945.60	507.26
Proceeds from long/short term borrowings	28.13	(30.25)
Repayment of borrowings		
Net Cash from Financing Activities	973.73	477.01
Net Increase in Cash & Cash Equivalents	(125.87)	247.99
Add : Opening Cash & Cash Equivalents	248.24	0.25
Cash and Cash equivalents at the end of the year	122.36	248.24

As per Our report of even date
For PPKG & Co
Chartered Accountants,
F.R.No.096555

Sd/-
Girdhari Toshniwal
PARTNER
Membership No: 205140
UDIN:26205140VEQLOS2924

Place: HYDERABAD
Date: 14/05/2026

For and on behalf of the Board of Directors of
Venmax Drugs and Pharmaceuticals Limited

Sd/-
Dasi Reddy Rakesh
Director
DIN: 07112785

Sd/-
K. Sai Baba
Chief Financial Officer

Sd/-
Venkata Rao Sadhanala
Managing Director
DIN: 02906370

Sd/-
Priyanka Agarwal
Company Secretary &
Compliance Officer

Notes on Financial Statements for the Financial year ended on March 31, 2026

1. Corporate information

The company is a public limited company incorporated under Companies Act, 1956 and domiciled in India bearing CIN: L24230TG1988PLC009102 having registered office at Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad, Secunderabad, Telangana, India, 500009. Its shares are listed on the BSE Limited. The Company is engaged in the business of pharmaceutical products, drug intermediaries and API's

2. Implementation of Ind As

All applicable Ind AS have been applied consistently and retrospectively wherever required. The resulting difference between the carrying amounts of the assets and liabilities in the standalone financial statements under both Ind AS and Indian GAAP as of the transition date have been recognized directly in equity at the transition date.

3. Basis of Preparation and Significant Accounting policies

3.1 (a) Basis of preparation of financial statements and measurement.

The standalone financial statement has been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016 and other relevant provisions of the Act.

These financial statements have been prepared to comply in all material respects with the Accounting Standards notified by Companies (Accounting Standards) Rules, 2006, (as amended) and the relevant provisions of the Companies Act, 1956/2013 read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Indian GAAP). The financial statements have been prepared under the historical cost convention on an accrual basis and going concern basis. The accounting policies that have been consistently applied by the company are consistent with those used in the previous year.

(b) Functional and Presentation Currency

The Financial Statements are prepared in Indian Rupees ("INR") which is the Company's Functional Currency for its Operations. All Financial Information presented in INR has been rounded to the nearest 'lakhs' with two decimal places, unless stated otherwise.

3.2 Use of estimates

The preparation of Financial Statements in conformity with the Ind AS requires the Management to make estimates, judgements, and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period.

Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcome requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

3.3 Significant Accounting Policies

(a) Revenue Recognition

- i. Revenue is recognized when the significant risks and rewards of ownership have been transferred to the customers. Revenue is measured net of returns, trade discounts and volume rebates. The timing of the transfer of risks and rewards varies depending on the individual terms of the sales agreement.
- ii. Revenues from contracts priced on a time and material basis are recognized when services are rendered and related costs are incurred.
- iii. Revenues from turnkey contracts, which are generally time bound fixed price contracts, are recognised over the life of the contract using the proportionate completion method, with contract costs determining the degree of completion. Foreseeable losses on such contracts are recognised when probable.

- iv. Revenues from maintenance contracts are recognised pro-rata over the period of the

contract.

- v. Revenue from sale of goods will be recognized when the delivery of goods has happened, and ownership is transferred to buyer.
- vi. Interest income is recognized on the accrual basis using transactional interest rates.

(b) Property, Plant and Equipment (PPE)

- i. All fixed assets are stated at cost of acquisition or construction less accumulated depreciation.
- ii. Recognition and measurement: Normally Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Cost includes expenditures directly attributable to the acquisition of the asset. The Company has elected to apply the optional exemption to use this previous GAAP value as deemed cost on 1 April 2017, the date of transition.
- iii. Depreciation has been provided on WDV method based on life assigned to each asset in accordance with Schedule II of the Companies Act 2013.
- iv. Depreciation on additions to fixed assets has been calculated on pro-rata basis from the date of addition.
- v. No depreciation has been provided on the fully depreciated assets.

(c) Borrowing cost

Borrowing costs attributable to the acquisition/construction of qualifying assets are capitalized and form part of the cost of the qualifying assets. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are charged to revenue as an expense.

(d) Income Tax

Current Tax is determined as the amount of tax payable in respect of taxable income for the period. Deferred Tax is recognized, on timing differences, being the difference between taxable Income and accounting Income that originates in one period and are capable of reversal in one or more subsequent periods. Deferred Tax assets are recognized subject to the consideration of prudence. The tax rates and laws that have been enacted or substantively enacted as of the balance sheet date are applied.

(e) Inventories

Inventories are measured at lower of cost and net realizable value after providing for obsolescence, if any. Cost of inventories comprises of cost of purchase, cost of conversion and other cost including manufacturing overheads incurred in bringing them to their respective present location and condition. Cost of raw materials, work-in-progress, packing materials, trading and other products are determined on first-in-first-out basis.

(f) Deferred Revenue Expenditure

Expenditure incurred on advertisement and other expenses for promotion of new products and recruitment of key personnel is amortized over a period of five years, having due regard to the nature of expenses and the benefit that may be derived there from. Expenditure on routine product advertisement and personnel recruitment is expensed off to profit & loss account in the year in which it is incurred.

(g) Cash and cash equivalents

Cash and cash equivalents for the purposes of cash flow statement comprise cash at bank and in hand and short-term deposits with banks with an original maturity of three months or less.

(h) Cash Flow Statement

Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

(i) Loans and borrowings

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost. Gains and losses are recognised in profit and loss when the liabilities are derecognized. This category generally applies to interest-bearing loans and borrowings.

(j) Foreign currency transactions

Transactions arising in foreign currency during the year are recorded at average rates closely approximating those ruling at the transaction dates. Current Assets and Current Liabilities, denominated in foreign currency, are translated at the exchange rate prevalent at the date of the Balance Sheet. Exchange differences arising on foreign currency transactions/translations are recognized as income or expense in the Profit & Loss Account, except those relating to the acquisition of fixed assets, which are adjusted against the cost of the assets.

(k) Leases

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item, are classified as operating leases. Operating lease payments are recognized as an expense in the Statement of Profit and Loss on a Straight - line basis over the lease term.

(l) Employee benefits

All Employee Benefits payable for rendering the service such as Salaries, Wages etc. and the expected cost of ex-gratia are recognised in the period in which the employee renders the related service. A Liability is recognised for the amount expected to be paid when there is a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

(m) Provisions, Contingent Liabilities and Contingent Assets

Provisions are recognised when the Company has a Present Obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Contingent Liability is disclosed in case of a present obligation arising from past events, when it is not probable that an outflow of resources will be required to settle the obligation or where no reliable estimate is possible. Contingent Liabilities are not recognised in Financial Statements but are disclosed in the Notes to Accounts. Contingent Asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Entity. Contingent Assets are not recognised in Financial Statements and are disclosed in the Notes when it is virtually certain that economic benefits will inflow to the Company.

(n) Earnings per share (EPS)

Basic EPS is computed using the weighted average number of equity shares outstanding during the period. Diluted EPS is computed using the weighted average number of equity and dilutive equity equivalent shares outstanding during the period except where the results would be anti-dilutive.

Notes forming part of the financial statements

Note 3

(Rs. in lakhs)

S. No	Description of Asset	Gross Block 01/04/2025	Rate of Depreciation	Depreciation as on 31/03/2026	sale	Net Block as on 31/03/2026	Net Block as on 31/03/2025
					31-03-2026		
1	Computers	0.002	31.67%	0.001		0.001	0.002
2	Computers	0.013	31.67%	0.004		0.009	0.013
3	Computers	0.006	31.67%	0.002		0.004	0.006
4	Computers	0.016	31.67%	0.005		0.011	0.016
5	Computers	0.019	31.67%	0.006		0.013	0.019
Sub Total		0.055		0.017		0.038	0.055
6	Furniture	3.992	9.50%	0.38		3.613	3.992
Sub Total		3.992		0.38		3.613	3.992
Grand Total		4.047		0.40		3.651	4.047

4. Inventories

(Rs. In Lakhs)

Particulars	31-03-2026	31-03-2025
Closing stock	99.88	5.75
	99.88	5.75

5. Trade Receivables

(Rs. In Lakhs)

Particulars	31-03-2026	31-03-2025
Unsecured, Considered Good		
Trade Receivables	143.00	95.26
	143.00	95.26

Ageing Schedule as at 31-03-2026

Particulars	Outstanding for following periods from due date of payment						
	Less than 6 months	6 months-1year	1-2 years	2-3 years	More than 3 years	2- 3 years	Total
(i) Undisputed Trade receivables - considered good	143.00	-	-	-	-	-	143.00
(ii) Undisputed Trade Receivables - considered doubtful	-	-	-	-	-	-	-
(iii) Disputed Trade Receivables considered good	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-	-

Ageing Schedule as at 31-03-2025

Particulars	Outstanding for following periods from due date of payment						
	Less than 6 months	6 months-1year	1-2 years	2-3 years	More than 3 years	2- 3 years	Total
(i) Undisputed Trade receivables - considered good	95.26	-	-	-	-	-	95.26
(ii) Undisputed Trade Receivables - considered doubtful	-	-	-	-	-	-	-
(iii) Disputed Trade Receivables considered good	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-	-
Total	95.26	-	-	-	-	-	95.26

6. Cash and cash equivalents

Particulars	(Rs. In lakhs)	
	31-03-2026	31-03-2025
Cash in Hand	0.02	0.02
Bank accounts		
ICICI Bank Account No-630805161865	16.15	2.85
ICICI Share Application 2267	100.09	242.25
IDFC Bank-1010	6.10	3.11
IDBI bank account		0.01
	122.36	248.24

7. Other Financial Assets

Particulars	(Rs. In lakhs)	
	31-03-2026	31-03-2025
Loans to Related Parties	565.40	161.00
Other Advances	169.58	-
	734.97	161.00

8. Other current assets

Particulars	(Rs. In lakhs)	
	31-03-2026	31-03-2025
Fixed Deposits with Other Bank	501.28	
Balance with government authorities	12.21	2.67
Employee advances	1.00	
Others	1.66	
	516.14	2.67

9 Statement of changes in equity for the period ended 31-03-2026

Equity Share Capital

(Rs. In lakhs)

Particulars	31-03-2026	31-03-2025
Authorised		
2,20,00,000(2,20,00,000) Equity Shares Capital of Rs 10/- Par value	2,200.00	2,200.00
	2,200.00	2,200.00
Issued		
1,15,82,930 (52,38,930) Equity Shares Capital of Rs. 10/- Par Value	1,158.29	523.89
	1,158.29	523.89
Subscribed		
1,15,82,930 (52,38,930) Equity Shares Capital of Rs. 10/- Par Value	1,158.29	523.89
	1,158.29	523.89
Paidup		
1,15,82,930 (52,38,930) Equity Shares Capital of Rs. 10/- Par Value	1,158.29	523.89
	1,158.29	523.89

Holding More Than 5%

Particulars	31-03-2026		31-03-2025	
	Number of Share	% Held	Number of Share	% Held
VENKAT NARENDER NUKA	9,26,775.00	8%	9,26,775.00	17.69%
JUGAL KISHORE BHAGAT	13,00,000.00	11.22%		
PUSHPA BHAJU	15,00,000.00	12.95%	-	-
PERCY HOMI ITALIA	-	-	4,66,161.00	8.90%
DR TADLA TIRUMAL RAO	-	-	2,84,900.00	5.44%

Reconciliation

Particulars	31-03-2026		31-03-2025	
	Number of Share	Amount	Number of Share	Amount
Number of shares at the beginning	52,38,930.00	5,23,89,300.00	52,38,930.00	5,23,89,300.00
Add: Issue				
Shares issued	63,44,000.00	63,4,40,000.00		
Less: Bought Back				
Others				
Number of shares at the end	1,15,82,930.00	11,58,29,300.00	52,38,930.00	5,23,89,300.00

10. Other Equity

(Rs. In lakhs)

Particulars	31-03-2026	31-03-2025
Profit and Loss Opening	-589.94	-588.89
Amount Transferred from Statement of P&L	24.82	-1.05
	-565.12	-589.94
	-565.12	-589.94
Share application money pending allotment	184.05	507.25
Securities Premium	634.40	-

11. Short Term Borrowings

(Rs. In lakhs)

Particulars	31-03-2026	31-03-2025
(a) Non-current		
Unsecured		
Loan from related parties	4.96	4.96
	4.96	4.96
(b) Current		
Loan from related parties	5.00	-
Loan from Others	23.13	-
	28.13	-

12. Deferred Tax Liabilities

(Rs. In lakhs)

Particulars	31-03-2026	31-03-2025
Deferred Tax Assets		
Property, Plant and Equipment	0.10	0.10
	0.10	0.10

13. Other Financial Liabilities

(Rs. In lakhs)

Particulars	31-03-2026	31-03-2025
Current		
Payable to employees	1.81	0.85
	1.81	0.85

14. Trade Payables

as at 31-03-2026

(Rs. In lakhs)

Particulars	Outstanding for following periods from due date of payment				Not Due	Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years		
(i) MSME	-	-	-	-	-	-
(ii) Others	155.61	12.12	-	-	-	167.73
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-

as at 31-03-2025

(Rs. In lakhs)

Particulars	Outstanding for following periods from due date of payment				Not Due	Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years		
(i) MSME	-	-	-	-	-	-
(ii) Others	55.06	7.81	-	-	-	62.87
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-

15 Provisions

(Rs. In lakhs)

Particulars	31-03-2026	31-03-2025
Current		
Others	3.81	0.70
	3.81	0.70

16 Other Liabilities

(Rs. In lakhs)

Particulars	31-03-2026	31-03-2025
Current		
Statutory dues	0.33	1.9
Others	1.54	4.4
	1.86	6.3

17 Revenue from Operations

(Rs. In lakhs)

Particulars	31-03-2026	31-03-2025
Revenue from operations	802.49	80.73
	802.49	80.73

18 Other Income

(Rs. In lakhs)

Particulars	31-03-2026	31-03-2025
Interest income on:		
Fixed Deposits	13.66	-
Other Expenses written back	2.38	105.32
	16.04	105.32

19. Purchases

(Rs. In lakhs)

Particulars	31-03-2026	31-03-2025
Purchases	822.27	85.21
	822.27	85.21

Changes in Inventories of Finished Goods, WIP and Stock in Trade

(Rs. In lakhs)

Particulars	31-03-2026	31-03-2025
Opening Stock	5.75	-
Closing stock	99.88	5.75
Increase/Decrease	(94.13)	(5.75)
	(94.13)	(5.75)

20. Employee benefits expense**(Rs. In lakhs)**

Particulars	31-03-2026	31-03-2025
Salary, Wages & Bonus	18.56	4.00
Staff Welfare Expenses	1.10	0.04
	19.67	4.04

21 Depreciation and amortisation expense**(Rs. In lakhs)**

Particulars	31-03-2026	31-03-2025
Depreciation & Amortisation		
Depreciation on Tangible Assets and Intangible Assets	0.40	0.48
	0.40	0.48

22 Other expenses**(Rs. In lakhs)**

Particulars	31-03-2026	31-03-2025
Indirect expenses		
Administrative and General Expenses	0.68	-
Amalgamation Expenses	8.90	-
Annual Listing Fees	3.25	23.27
Audit Fee	1.15	1.45
Bank charges	0.08	0.08
Professional & consultancy charges	1.41	7.32
Electricity charges	0.63	-
Rates and taxes	-	0.20
Communication expenses	0.13	-
BSE, CDSL and NSDL charges	1.93	46.22
ESI Fund A/c	-	6.96
Donation	0.12	-
Preferential Issue Expenses	-	12.60
Travelling and conveyance	0.31	0.17
Rent Expenses	0.60	1.87
Repairs and maintenance		
Building	0.09	-
Others	0.20	0.04
RTA Expenses	1.75	-
Postage and courier charges	0.01	-
Advertisement expenses	0.69	0.67
Office maintenance expenses	0.72	0.16
Printing and stationery	0.46	-
Writeoff Intangible Asset	-	1.87
Miscellaneous expenses	0.00	0.45
Penalties	15.71	-
Share Warrant expenses	3.80	-
	42.64	103.31

23 Tax expense**(Rs. In lakhs)**

Particulars	31-03-2026	31-03-2025
Current tax		
CURRENT TAX	2.88	0.00
DEFERRED TAX ASSET	(0.01)	(0.36)
	2.81	(0.36)

24 Earnings per equity share**(Rs. In lakhs)**

Particulars	31-03-2026	31-03-2025
Earnings Per Equity Share		
Basic	0.21	(0.02)
Diluted	0.21	(0.02)
Number of Shares used in computing EPS		
Basic	115.83	52.39
Diluted	115.83	52.39
Weighted Average Number of shares		
Number of Shares for basic EPS calculation	115.83	52.39

25. Government Subsidy

Subsidy from the Government is recognized when there is reasonable assurance that the company will comply with the conditions attached to them.

ADDITIONAL INFORMATION TO THE FINANCIAL STATEMENTS

26. Share Capital

There has been no change in the authorised share capital of the Company during the Financial Year 2025-26. However, the paid-up share capital of the Company has increased from Rs. 523.89 lakhs to Rs. 1,158.29 lakhs during the year. Out of which, The Company has allotted all 63,44,000 equity shares of face value ₹10 each at an issue price of ₹20 per share (including a premium of ₹10 per share) to non-promoter allottees upon conversion of warrants issued on a preferential basis. The equity shares allotted bear distinctive numbers from 52,38,931 to 1,15,82,930 and rank pari passu with the existing equity shares of the Company in all respects.

27. Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006

As at 31st March, 2026, the Company has no dues to suppliers registered under Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act'). The disclosures pursuant to the said MSMED Act are as follows:

Particulars	Year ended 31st March, 2026	Year ended 31st March, 2025
a) The principal amount remaining unpaid to any supplier at the end of the year	0	0
b) Interest due remaining unpaid to any supplier at the end of the year	0	0
c) The amount of interest paid by the buyer in terms of section 16 of the MSMED Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during the year	0	0
d) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act, 2006	0	0
e) The amount of interest accrued and remaining unpaid at the end of each accounting year	0	0
f) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprises, for the purpose of disallowance of a deductible expenditure under section 23 of the MSMED Act, 2006	0	0

Disclosure of payable to vendors as defined under the "Micro, Small and Medium Enterprise Development Act, 2006" is based on the information available with the Company regarding the status of registration of such vendors under the said Act, as per the intimation received from them on requests made by the Company. There are no overdue principal amounts / interest payable amounts for delayed payments to such vendors at the Balance Sheet date. There are no delays in payment made to such suppliers during the year or for any earlier years and accordingly there is no interest paid or outstanding interest in this regard in respect of payment made during the year or on balance brought forward from previous year.

28. Disclosure under regulation 34 (3) of SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015

The Company does not have any subsidiaries.

29. Related Party disclosure as required by Accounting standard (AS) 18 “Related Party Disclosure”

Related Party	Nature of Relationship	Nature of Transaction	Amount (₹ in Lakhs)	Outstanding Balance (₹ in Lakhs)
Sadhanala Venkata Rao	Director	Long Term Borrowings	7.00	7.00
Somani Herbs and Agro Products India Private Limited	Company having common Directors	Long Term Borrowings	2.96	2.96
Blue Nile Capital Advisory Ltd	Company having common directors	Loans and Advances	562.55	562.55
Omega AG Seeds Punjab Ltd	Company having common directors	Loans and Advances	2.85	2.85

30. Applicability of IND AS 108

The Company operates in a Single Segment. Accordingly, disclosures under Indian Accounting Standards (IND AS) 108 on operating segments are not applicable to the company.

31. Details of Auditors’ Remuneration (Excluding GST)

(in lakhs)

Sr. No	Particulars	2025-26	2024-25
1	Statutory Audit Fee	0.55	0.85
2	Certification & Other services	0.60	0.60

32. Additional information pursuant to Note 5 of Part II of Schedule III of the Companies Act, 2013: Foreign Exchange Transactions

There were no foreign Exchange transactions during the year 2025-26. (Previous year Nil)

33. Capital commitment and contingent liabilities**a. Capital commitment**

There are no capital commitment outstanding as at reporting date March 31, 2026 (as at March 31, 2025: NIL)

b. Contingent Liabilities and Commitments

There are no contingent liabilities.

34. The Disclosures of Employee Benefits:

Since there are only 2 employees during the year, no provision has been created for Gratuity or other retirement benefits.

35. Taxes and Deferred

During the year, the Company has earned profits, which have been adjusted against the brought forward losses. Accordingly, no provision for current income tax has been made. Further, Deferred Tax Asset in respect of carried forward losses has not been recognized, considering the uncertainty regarding the availability of sufficient future taxable profits as at the balance sheet date.

36. Other Statutory Information:

- (i) The Company has not been declared willful defaulter by any bank or financial institution or government or any government authority.
- (ii) The Company has not granted Loans or Advances in the nature of loans to promoters, directors, KMPs and the related parties.
- (iii) The Company does not have any transactions with companies which are struck off.

37. Scheme of Amalgamation

The Board of Directors of the Company at its meeting held on 12th November 2025 approved a Scheme of Amalgamation under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, providing for the amalgamation of Hatri Pharma Private Limited ("Transferor Company") with Venmax Drugs and Pharmaceuticals Limited ("Transferee Company").

The company has got the NOC from BSE dated 15/05/2026 and the same is subject to the approval National Company Law Tribunal (NCLT).

Pending receipt of the aforesaid approvals, no effect of the proposed amalgamation has been given in these financial statements. The management does not expect any material impact on the carrying value of assets and liabilities as at the reporting date, except to the extent that may arise upon implementation of the Scheme.

38. Events Occurring After the Reporting Period

Subsequent to the reporting date, the Company received the NOC from BSE Limited vide letter dated 15 May 2026 in connection with the proposed Scheme of Amalgamation of the Company with Hatri Pharma Private Limited.

The Scheme continues to be subject to the approval of the National Company Law Tribunal (NCLT) and other applicable regulatory approvals and has not yet become effective. Accordingly, no effect of the proposed amalgamation has been given in these financial statements.

39. Previous year's figures have been regrouped/reclassified wherever necessary to correspond with the current year's classification/disclosure.

As per Our report of even date
For PPKG & Co
Chartered Accountants,
F.R.No.096555

Sd/-
Girdhari Toshniwal
PARTNER
Membership No: 205140
UDIN:26205140VEQLOS2924

Place: HYDERABAD
Date: 14/05/2026

For and on behalf of the Board of Directors of
Venmax Drugs and Pharmaceuticals Limited

Sd/-
Dasi Reddy Rakesh
Director
DIN: 07112785

Sd/-
K. Sai Baba
Chief Financial Officer

Sd/-
Venkata Rao Sadhanala
Managing Director
DIN: 02906370

Sd/-
Priyanka Agarwal
Company Secretary &
Compliance Officer

Venmax Drugs and Pharmaceuticals Limited

CIN: L24230TG1988PLC009102

SY No. 115, Brig Sayeed, Hanumanji Colony,
Bowenpally, Picket, Hyderabad, Secunderabad,
Telangana, India, 500009

E-mail: Venmaxdrugs@gmail.com

Website: www.venmaxdrugs.com